

PERSONAL INFORMATION

Harry J M Groen

WORK EXPERIENCE

October 2003-June 2022

Professor in Thoracic Oncology, Department of Respiratory Medicine

University Medical Centre Groningen (Netherlands)

From 01-11-2022 working at Department of Pulmonary Diseases, UMC Utrecht

EDUCATION AND TRAINING

1978-

MD

University Utrecht, The Netherlands ()

being medical doctor

1995-

Doctorate

University Groningen, The Netherlands ()

Having PhD status

2003-June 2022

Professor, lung cancer

University Groningen, The Netherlands ()

Diagnosis and treatment of Lung Cancer

ADDITIONAL INFORMATION

Expertise

Diagnosis and treatment of Lung Cancer

Publications

Groen HJM, Dolman B, Pijpers P, Lockefer J. Castleman disease. Ned. Tijdschr Geneesk 1988; 132: 1937-1939

Groen HJM, Smit EF, Haaxma-Reiche H, Postmus PE. Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer. Eur J Cancer, 29A,12,199-3,1696-1699

Groen HJM, Bogaard JM, Balk AHMM, Kho SG, Hop WCJ, Hilvering C. Diffusion capacity in heart transplant recipients. Letter to the Editor. Chest, 104,6,1993,1938-39

De Man RA, Hilvering C, Groen HJM, Balk AHMM. Nocardiose: een verradelijke gegeneraliseerde infectieziekte. Ned Tijdschr Geneesk, 1993;137;577-579.

Smit EF, Groen HJM, Timens W, De Boer WJ, Postmus PE. Surgical resection for small cell carcinoma of the lung: a retrospective study. Thorax 1994; 49: 20-22

Groen HJM, Van der Leest AHD, De Vries EGE, Uges DRA, Szabo BG and Mulder NH. Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study. Br J Cancer, 1995: 72;992-997.

Groen HJM, Sleijfer S, Meijer C, Kampinga HH, Konings AWT, De Vries EGE, Mulder NH. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. Br J Cancer, 1995;72;1406-1411.

Veldhuis GJ, Willemse PHB, Sleijfer DT, Van der Graaf WTA, Groen HJM, Limburg PC, Mulder NH, De Vries EGE. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small cell lung cancer. J Clin Oncol, 1995;13;2585-2593.

Bakker M, Groen HJM, Smit EF, Smeets J, Riggi M, Postmus PE. Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small cell lung cancer IIIB-IV. Br J Cancer, 1995;72;1547-1550.

Bakker, M, van der Graaf, WTA, Groen, HJM, Smit EF, De Vries, EGE.

Anthracyclines - Pharmacology and resistance, a review. Curr Pharm Design, 1995,1,-133-144.

Groen HJM. Exploration of a new therapy for lung cancer. Thesis, University of Groningen, 1995

Kosterink JWG, De Jonge MWA, Smit EF, Piers DA, Kengen RAM, Postmus PE, Shochat D, Groen HJM, The HT, De Leij L. Pharmacokinetics and scintigraphy of indium-111-DTPA-MOC-31 in small

cell lung carcinoma. *J Nucl Med*, 36:2356-2362;1995

Groen HJM, Meijer C, De Vries EGE, Mulder NH. Red blood cell glutathione levels in lung cancer patients treated by radiation and continuously infused carboplatin. *Anticancer Res*, 1996, 16, 1033-1038.

BAM The, GH Koeter, HJM Groen. Wij kunnen U wel behandelen: over patienten met een kleincellig bronchuscarcinoom. *NTVG*, 1996, 140, 2021-2023.

Gatzemeier U, Shepherd FA, LeChevalier T, Weynants P, Cottier B, Groen HJM, Rosso R, Mattson K, Cortes-Funes H, Tonato M, Burkes RL, Gottfried M, Voi M. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. *Eur J Cancer*, 32A,2, 243-248,1996.

Groen H.J.M. Nieuwe therapeutische benadering van longkanker. *Tijdschrift Kanker*, 20:4;30-32,1996.

Groen H.J.M. Een nieuw therapeutische benadering van het longcarcinoom. *Pulmo-script*, 1996, 2, 34-36.

Smit EF, Groen HJM, Splinter TAW, Ebels T, Postmus PE. New prognostic factors in resectable non-small cell lung cancer. *Thorax*, 1996, 51, 638-646.

Van Meerbeeck J., Debruyne C., Van Zandwijk N., Postmus P.E., Pennucci M.C., Van Breukelen F., Galdermans D., Groen H.J.M., Pinson P., Van Glabbeke M., Van Marck E., Giaccone G. Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. *Br J Cancer*, 74:961-963;1996.

Postmus PE, Scagliotti G, Groen HJM, Gozzelino F., Burghouts JThW, Curran D, Sahmoud T, Kirkpatrick A, Giaccone G, Splinter TAW. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC phase III trial. *Eur J Cancer*, 32A, 9, 1498-1503, 1996.

Jager P.L., Franssen E.J.F., Kool W., Vaalburg W., Szabo B.G., Hoekstra H.J., Groen H.J.M., de Vries E.G.E., Piers D.A. Initial evaluation of tumor imaging using L-3-[123I]-iodo-alpha-methyl-tyrosine in extra-cranial tumors. in press.

RS de Jong, NH Mulder, DRA Uges, S Kaul, B Winograd, DTH Sleijfer, HJM Groen, PHB Willemse, WTA de Graaf, EGE de Vries. Randomized comparison of etoposide pharmacokinetics after etoposide phosphate and oral etoposide. *Br J Cancer*, 75:1660-1666;1997.

Vujaskovic Z., Groen H.J.M. Preservation of the lung function after thoracic irradiation: role of transforming growth factor beta (TGF- β). *Radiol. Oncol.* 31:233-235,1997.

N. van Zandwijk, H.J.M. Groen, P.E. Postmus, J. Th. W. Burghouts, G.P.M. Ten Velde, A. Ardizzoni, I.E. Smith, P. Baas, T. Sahmoud, A. Kirkpatrick, O. Dalesio, G. Giaccone for the EORTC. Role of recombinant Interferon-gamma maintenance in responding patients with small cell lung cancer. A randomized phase III study of the EORTC Lung Cancer Cooperative Group. *Eur J Cancer*, 33:1759-1766, 1997.

M. Bakker, J. Renes, A. Groenhuijzen, P. Visser, H. Timmer-Bosscha, M. Muller, H.J.M. Groen, E.F. Smit, E.G.E. de Vries. Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines. *Int J Cancer*, 73:362-366; 1997.

Smit E.F., Fokkema E., Biesma B., Groen H.J.M., Snoek W., Postmus P.E. A phase II study of paclitaxel in heavily pretreated patients with small cell lung cancer. *Br J Cancer*, 77:347-351;1997.

Jager PJ., Franssen E.J.F., Kool W., Szabo B.G., Hoekstra H.H., Groen H.J.M., de Vries E.G.E., van Imhoff G.W., Vaalburg W., Piers D.A. Feasibility of tumor imaging using L-3[123I]-iodo-methyl-tyrosine in extracranial tumors. *J Nucl Med*, 39:1736-1743;1998.

Kroesen B.J., Nieken J., Sleijfer D.Th., Molema G., de Vries E.G.E., Groen H.J.M., Helfrich W., The T.H., Mulder N.H., de Leij L. Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1. *Cancer Immun Therapy*, 1998.

Bakker M., Droz J.P., Hanauske A.R., Verweij J., van Oosterom A.T., Groen H.J.M., Pacciarini M.A., Domenigoni L., van Weissenbruch F., Pianezola E., de Vries E.G.E. Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. *Br J Cancer*, 77:139-146;1998.

Postmus P.E., Haaxma-Reiche H., Gregor A., Groen H.J.M., Lewinski T., Scolard T., Kirkpatrick A., Curran D., Sahmoud T., Giaccone G. Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. *Radiotherapy and oncology*, 46:29-32;1998.

Baas P., van Meerbeeck J., Groen H.J.M., Daamen S., van Glabbeke M., and Giaccone G. For the EORTC Lung Cancer Cooperative Group. Liposomal doxorubicin in malignant pleural mesothelioma (MM); an EORTC phase II study.

Jager PJ., Franssen E.J.F., Kool W., Szabo B.G., Hoekstra H.H., Groen H.J.M., de Vries E.G.E., van Imhoff G.W., Vaalburg W., Piers D.A. Feasibility of tumor imaging using L-3-[Iodine-123]-Iodo--methyl-tyrosine in extracranial tumors. *J Nucl Med*, 39:1736-1743;1998.

RS de Jong, NH Mulder, DRA Uges, DT Sleijfer, FJP Hoppener, HJM Groen, PHB Willemse, WTA de Graaf and EGE de Vries. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. *Br J Cancer*, 79:882-887;1999.

Harry J.M. Groen, Eelco Fokkema, Bonne Biesma, Bibi Kwa, John W.G. van Putten, Pieter E. Postmus, and Egbert F. Smit. Paclitaxel and Carboplatin in the Treatment of Small Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non Cross Resistant Schedule J Clin Oncol, 17:927-933;1999.

JP. Van Meerbeeck, P. Baas, Ch. Debruyne, HJM. Groen, C. Manegold, A. Ardizzoni, C. Gridelli, EA. Van de Marck, M. Lentz, G. Giaccone for the EORTC Lung Cancer Cooperative Group. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. *Cancer* 1999;85:2577-82.

Harry J.M. Groen, Eelco Fokkema, Bonne Biesma, Bibi Kwa, John W.G. van Putten, Pieter E. Postmus, and Egbert F. Smit. Paclitaxel and Carboplatin in the Treatment of Small Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non Cross Resistant Schedule J Clin Oncol, 17:927-933;1999.

JP. Van Meerbeeck, P. Baas, Ch. Debruyne, HJM. Groen, C. Manegold, A. Ardizzoni, C. Gridelli, EA. Van de Marck, M. Lentz, G. Giaccone for the EORTC Lung Cancer Cooperative Group. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. *Cancer* 1999;85:2577-82.

Bakker M., Van der Graaf WTA., Piers D.A., Franssen E.J.F., Groen H.J.M., Smit E.F., Kool W., Hollema H., Muller E.A., de Vries E.G.E. 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours. *Anticancer Res*, 19:2349-53;1999.

JWG van Putten, NJJ Schlosser, Z. Vujaskovic AHD van der Leest, HJM Groen. Superior vena cava obstruction caused by radiation induced venous fibrosis. *Thorax*, 55:0-1, 2000.

Fokkema E, de Vries EG, Meijer S, Groen HJM. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients. *Cancer Chemother Pharmacol*, 2000,45:89-92.

JWG van Putten, P.Eppinga, Z. Erjavic, G. van de Leede, J. Nabers, JBE Smeets, DTh. Sleijfer, HJM. Groen. Activity of high-dose epirubicin combined with gemcitabine in advanced non-small cell lung cancer: a multicenter phase I and II study. *Br J Cancer*, 82:806-811;2000.

E. Fokkema, J. Verweij, AT. van Oosterom, DRA Uges, R. Spinelli, O. Valota, EGE de Vries, HJM. Groen. A prolonged methoxymorpholinodoxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase I and pharmacokinetic study. *Br J Cancer*, 82:767-771;2000.

Theunissen DJ., Koopmans P., Hospers GAP., Stokman MA., Groen HJM., Uges DRA. Op zoek naar een succesvolle toepassing van WR-1065. Actieve metaboliet van amifostine ter voorkoming van mucositis. *Pharmaceutisch Weekblad*, 135:566-570, 2000.

Z. Vujaskovic and H.J.M. Groen. TGF-, radiation-induced pulmonary injury and lung cancer. *Int J Radiat Biol*, 76:511-516;2000.

W.T.A. van der Graaf, H.J.M. Groen, T.S. van der Werf, J.J. Meuzelaar, D.Th. Sleijfer. A young female with an endodermal sinus tumor in a pericardial localized cyst. *Acta Oncologica*, 39:244-246;2000.

PE. Postmus, H. Haaxma-Reiche, E.F. Smit, H.J.M. Groen, H. Karnicka, T. Lewinski, J. van Meerbeeck, M. Clerico, A. Gregor, D. Curran, T. Sahnoud, A. Kirkpatrick, G. Giaccone: Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole brain radiotherapy. A phase III study of the EORTC Lung Cancer Cooperative Group. *J Clin Oncol*, 18:3400-3408, 2000.

RM. Pieterman, JWG. van Putten, JJ. Meuzelaar, EL. Mooyaart, W.Vaalburg, GH. Koeter, V. Vidler, J. Pruijm, HJM. Groen. Preoperative Staging of Non-Small-Cell Lung Cancer with Positron-Emission Tomography. *New England Journal of Medicine* 343: 254-261, 2000.

P. Baas, J. van Meerbeeck, H.Groen, H. Schouwink, S. Burgers, S. Daamen, G. Giaccone. Caelyx in malignant mesothelioma: a phase II EORTC study. *Ann of Oncol*, 11:697-700, 2000.

Paridaens R., Uges DR., Barbet N., Choi L., Seegers M., van der Graaf WT., Groen H.J., Dumez H., Buuren IV., Muskiet F., Capdeville R., Oosterom AT., de Vries EG. A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours. *Br. J. Cancer*, 83:594-601;2000.

H.J.M. Groen. Diagnose en stadiering. Post Tokyo Meeting. Complete Response, blz 2-3, 2000

Tjan-Heijnen VCG, Groen HJM, Schramel FMNH, Stoter G. Consensus conference on palliative treatment of stage IV non-small cell lung cancer. Consensus meeting of the Netherlands Society for Medical Oncology and the Taskforce on Lung Cancer of the Dutch Society of Physicians for Lung Diseases and Tuberculosis. *Neth J Med* 2001; 58(2):52-61.

Kerbusch T., van Putten J.W.G., Groen H.J.M., Huitema A.D.R., Mathot R.A.A., Beijnen J.H. Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients. *Cancer Chemother. Pharmacol* 2001, 48:53-61.

Kerbusch T., de Kraker J., Keizer H.J., van Putten J.W.G., Groen H.J.M., Jansen R.L.H., Schellens H.J.M., Beijnen J.H. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. *Clin. Pharmacokinet.*, 2001, 40(1): 41-62.

Jager P. L., Groen H. J. M., van der Leest A., van Putten J. W. G., Pieterman R. M., de Vries E. G. E., Piers D. A. L-3-[I-123]iodo-alpha-methyl-tyrosine SPECT in non-small cell lung cancer: Preliminary observations. *J Nucl Med*, 2001, 42(4):579-585.

van Putten J. W. G., Kerbusch T., Smit E. F., van Rijswijk R., Beijnen J. H., Sleijfer D. T., Groen H. J. M. Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancer. *Ann Oncol*, 2001; 12:6-792.

Van der Lee I., Smit EF., Van Putten JWG., Groen HJM., Schlosser NJJ., Postmus PE., Schramel FMNH. Single-agent gemcitabine in patients with resistant small-cell lung cancer. *Ann Oncol*, 2001, 12:557-561.

RM. Pieterman, JWG. van Putten, JJ. Meuzelaar, EL. Mooyaart, W.Vaalburg, GH. Koeter, V. Vidler, J. Pruijm, HJM. Groen. Preoperative Staging of Non-Small-Cell Lung Cancer with Positron-Emission Tomography. In: Chapter 3, Lung Cancer, The Year Book of Pulmonary Disease 2001. Editor-in-Chief J.R. Jett, Mosby, page 116-118.

H.J.M. Groen. Plaatsbepaling van PET (positronemissietomografie) bij het niet-kleincellig bronchuscarcinoom. In: Pulmo Probleem, Pulmo-Didact. Redactie: P.R.N. Dekhuijzen, E.H.J. van Haren, nr. 3, september 2001.

van Putten J. W. G., Groen H. J. M., Smid K., Peters G. J., Kampinga H. H. End-joining deficiency and radiosensitization induced by gemcitabine. *Cancer Research*, 2001, 61(4):1585-1591.

JWG van Putten, P Baas, H Codrington, HB Kwa, M Muller, N Aaronson, HJM Groen. Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer. *Lung Cancer* 2001;33:289-298.

H.A.M. Kerstjens, H.J.M. Groen, W. van de Bij. Recent advances in Respiratory Medicine. *BMJ*, 323:1349-1353.

Hendrikse NH., Bart J., de Vries EGE., Groen HJM., van der Graaf WTA., Vaalburg W. P-glycoprotein at the Blood-Brain Barrier and analysis of drug transport with positron-emission tomography. *J Clin Pharmacol*, 41:48S-54S;2001.

HJM. Groen, EGE. de Vries, W. Wynendaele, WTA. van der Graaf, E. Fokkema, MJ Lechuga, I. Poggesi, LY. Dirix, AT. van Oosterom. PNU-145156E - A novel angiogenesis inhibitor - in patients with solid tumors: a phase I and pharmacokinetic study. *Clin Cancer Res*, 7:3928-3933; 2001.

Kerstjens HAM., Groen HJM., van der Bij. Recent advances in respiratory medicine. *Br Med J*, 323:1349-1353;2001.

Pieterman RM., Que TH., Elsinga PH., Pruijm J., van Putten JWG., Willemsen ATM., Vaalburg W., Groen HJM. Comparison of 11C-Choline and 18F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. *J Nucl Med*, 43:167-172;2002.

JG Maring, ABP van Kuilenburg, J Haasjes, H Piersma, HJM Groen, DRA Uges, AH Van Gennip and EGE De Vries. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. *Br J Cancer*, 86:1028-1033;2002.

Fokkema E., Groen HJM, Helder MN., de Vries EGE, Meijer J. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. *Biochemical Pharmacology* 63:1989-1996;2002.

R. Pieterman, A.Willemsen, M. Appel, J. Pruijm, G. Koeter, W.Vaalburg, H. Groen. Visualization and assessment of the protein synthesis rate of lung cancer using carbon-11 tyrosine and positron emission tomography. *Eur J Nucl Med*, 29:243-247, 2002.

Kehrer DF., Bos AM., Verwey J., Groen HJM., Loos WJ., Sparreboom A., de Jonge MJ., Hamilton M., Cameron T., de Vries EGE. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. *J Clin Oncol*, 20:1222-1231;2002.

H.J.M.Groen. Positron emission tomography in lung cancer. *Imaging Decisions*, 6:4, 2002.

Eelco Fokkema, Harry JM Groen, Coby Meijer, Wim Timens, Steven de Jong, Elisabeth GE de Vries. The role of apoptosis-related genes in non-small cell lung cancer. *Clinical Lung Cancer*, 4:174-182;2002.

Joost Bart, Harry JM Groen, Winette TA van der Graaf, Harry Hollema, N Harry Hendrikse, Willem Vaalburg, Dirk T. Sleijfer, and Elisabeth EG de Vries. An oncological view on the blood-testis barrier. *Lancet Oncol* 3:357-363;2002.

Oude Nijhuis CSM, Daenen SMGJ, Vellenga E, Van der Graaf WTA, Gietema JA, Groen HJM, Kamps WA, De Bont ESJM. Fever and neutropenia: the role of cytokines in new treatment strategies. *Critical Reviews in Hematology/Oncology. Crit Rev Oncol Hematol.* 44:163-174, 2002.

Maring JG., Piersma H., Dalen van A., Groen HJM., Uges DRA., Vries de EGE. Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics. *Cancer Chemother Pharmacol* 51:167-173;2002

Fokkema E., De Vries EGE., Groen HJM., Meijer C., Timens W. Expression of apoptosis-related proteins in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment. *Virchows Archiv*, 2003

Maring JG., Piersma H., Dalen van A., Groen HJM., Uges DRA., Vries de EGE. Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics. *Cancer Chemother Pharmacol* 51:167-173;2003

Bart J., Willemsen ATM., Groen HJM., van der Graaf WTA., Wegman ThD., Vaalburg W., de Vries EGE., Hendrikse NH. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [¹¹C]verapamil measured with PET. *Neuroimage*, 20:1775-1782, 2003

Oude Nijhuis CSM, Vellenga E, Daenen SMGJ, Van der Graaf WTA, Gietema JA, Groen HJM, Kamps WA, De Bont ESJM. Lipopolysaccharide-binding protein: a diagnostic marker for gram-negative bacteremia in neutropenic cancer patients. *Intensive Care Med.* 2003 29:2157-2161, 2003

Oude Nijhuis CSM, Gietema JA, Vellenga E, Daenen SMGJ, de Bont ESJM, Kamps WA, Groen HJM, van der Jagt EJ, van der Graaf WTA. Routine radiography does not have a role for in the diagnostic evaluation of ambulatory adult febrile neutropenic cancer patients. *Eur J Cancer*, 39:2495-2498, 2003

Wachters FM., van Putten JWG., Maring JG., Zdzienicka MA., Groen HJM., Kampinga HH. Selective targeting of homologous DNA recombination repair by gemcitabine. *Int J Radiat Oncol Biol Phys* 57:553-562;2003.

Kramer H., Groen HJM. Current concepts in the mediastinal lymph node staging of nonsmall cell lung cancer. *Ann Surg* 238:180-188,2003.

Dodde WIW., Maring JG., Hendriks G., Wachters FM., Groen HJM., de Vries EGE., Uges DRA. Determination of epirubicin and its metabolite epirubicinol in saliva and plasma by HPLC. *Therapeutic Drug Monitoring* 25:433-440, 2003.

Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. *Clin Cancer Res* 2003; 9: 3397-405.

Wachters FM., van Putten JWG., Kramer H., Etjavic Z., Eppinga P., Strijbos JH., de Leede GPJ., Boezen HM., de Vries EGE., Groen HJM. First-line gemcitabine with cisplatin or epirubicin in advanced non-small cell lung cancer.: a phase III trial. *Brit J Cancer* 89:1192-1199;2003.

Kramer H. Groen HJM. Technical description of endoscopic ultrasonography with fine-needle Aspiration for the staging of lung cancer. *Respiratory Medicine* 2004.

Wachters FM, Van Putten JW, Boezen HM, Groen HJM. Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC. *Lung Cancer.* 45:255-262, 2004.

Kramer H, van Putten JW, Post WJ, van Dullemen HM, Bongaerts AH, Pruijm J, Suurmeijer AJ, Klinkenberg TJ, Groen H, Groen HJM. Oesophageal endoscopic ultrasound with fine needle aspiration improves and simplifies the staging of lung cancer. *Thorax.* 59:596-601, 2004.

Kramer H, Pieterman RM, Slebos DJ, Timens W, Vaalburg W, Koeter GH, Groen HJM. PET for the evaluation of pleural thickening observed on CT. *J Nucl Med.* 45:995-998, 2004.

Wachters FM, Groen HJM, Maring JG, Gietema JA, Porro M, Dumez H, de Vries EG, van Oosterom AT. A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. *Br J Cancer.* 90:2261-2267, 2004.

Kramer H, Nieuwenhuis JA, Groen HJM, Wempe JB. Pulmonary tuberculosis diagnosed by esophageal endoscopic ultrasound with fine-needle aspiration. *Int J Tuberc Lung Dis.* 8;272-273, 2004.

Novakova-Jiresova A, Van Gameren MM, Coppes RP, Kampinga HH, Groen HJM. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. *Radiother Oncol.* 71;183-189, 2004.

van Albada ME, Eldering MJ, Post WJ, Klinkenberg TJ, Timens W, Groen HJM. The biopsying of at least 5 mediastinal lymph node stations for presurgical staging in patients with a non-small-cell lung carcinoma. *Ned Tijdschr Geneesk.* 148;2891-286, 2004.

Groen HJM, van der Leest AH, Fokkema E, Timmer PR, Nossent GD, Smit WJ, Nabers J, Hoekstra HJ, Hermans J, Otter R, van Putten JW, de Vries EG, Mulder NH. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. *Ann Oncol.* 15;427-432, 2004.

Kramer H, Koeter GH, Sleijfer DT, van Putten JW, Groen HJM. Endoscopic ultrasound-guided fine-needle aspiration in patients with mediastinal abnormalities and previous extrathoracic malignancy. *Eur J Cancer.* 40;559-562, 2004.

Stokmans MA, Wachters FM, Koopmans P, Burgerhof JGM, Groen HJM, Spijkervet FKL, Uges DRA, Hospers GAP. Outcome of Local Application of Amifostine (WR-1065) on Epirubicin-induced Oral Mucositis. A Phase II Study. *Anticancer Research,* 24:3263-68, 2004.

Bart J., Hollema H., Groen HJM., de Vries EGE., Hendrikse NH., Sleijfer DT., Wegman TD., Vaalburg W., van der Graaf WTA. The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. *Eur J Cancer* 40: 2064-2070, 2004.

Wachters FM, Van Der Graaf WT, Groen HJ. Cardiotoxicity in advanced non-small cell lung cancer patients treated with platinum and non-platinum based combinations as first-line treatment. *Anticancer Res* 24:2079-83, 2004

J. Kosterink, HJM Groen et al. Biodistribution studies of ¹¹¹In-9N3-MOC-31 in the tumor bearing nude rat and in patients with small cell lung carcinoma. *J Nucl Med,* 2004.

Harry J.M. Groen. Innovations in mediastinal staging and response in lung cancer. Educational Sessions. American Society of Clinical oncology, 41st Annual Meeting, Orlando, 2005.

Nijhuis CO, Kamps WA, Daenen SM, Gietema JA, van der Graaf WT, Groen HJ, Vellenga E, Ten Vergert EM, Vermeulen KM, de Vries-Hospers HG, de Bont ES. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. *J Clin Oncol,* 2005, 23:7437-7444.

W.K. de Jong, W.T.A. van der Graaf, E.J. van der Jagt, T. J. Klinkenberg, H.J.M. Groen, W. Timens, en W.R. Douma. A 20-year-old male with thoracic pain and a lower thoracic mass. Diagnosis: intrathoracic desmoid tumour with microscopically incomplete resection. *Eur Respir J.* 2005, 26:740-743.

Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. *Lung Cancer,* 2005, 50:211-219.

Hoekstra R., Vos de FYFL., Eskens FALM., Gietema JA., Gaast van der A., Groen HJM., Knight RA., Carr RA., Humerickhouse RA., Verwey J., Vries de EGE. A phase I safety, pharmacokinetic and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. *J Clin Oncol* 23:5188-97, 2005.

Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. *Pharmacogenetics J,* 2005, 5:226-243.

Bart J, Dijkers EC, Wegman TD, de Vries EG, van der Graaf WT, Groen HJ, Vaalburg W, Willemsen AT, Hendrikse NH. New positron emission tomography tracer [¹¹C]carvedilol reveals P-glycoprotein modulation kinetics. *Br J Pharmacol,* 2005, 145:1045-1051.

Kramer H, Groen HJ. Diagnosis of mediastinal and left adrenal abnormalities with endoscopic ultrasonography. *Respir Med,* 2005, 99:926-928.

Nuver J, Lutke Holzik MF, van Zweeden M, Hoekstra HJ, Meijer C, Suurmeijer AJH, Groen HJM, Hofstra RM, Sluiter WJ, Groen H, Sleijfer DT, Gietema JA. Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients. *Pharmacogenet Genomics.* 2005, 15:399-405.

Harry J.M. Groen, Dirk Th. Sleijfer, Elisabeth G.E. de Vries. Positron emission tomography, computerized tomography, and endoscopic ultrasound with needle aspiration for lung cancer. American Society of Clinical Oncology, Educational Book, Orlando, 579-585, 2005.

Kramer H, van Putten JW, Douma WR, Smidt AA, van Dullemen HM, Groen HJ. Technical description of endoscopic ultrasonography with fine-needle aspiration for the staging of lung cancer. *Respir Med*, 2005, 99:179-185.

Wachters FM, Groen HJ, Biesma B, Schramel FM, Postmus PE, Stigt JA, Smit EF. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. *Br J Cancer*, 2005, 92:15-20.

Herder GJ, Kramer H, Hoekstra OS, Smit EF, Pruim J, van Tinteren H, Comans EF, Verboom P, Uyl-de Groot CA, Welling A, Paul MA, Boers M, Postmus PE, Teule GJ, Groen HJ; POORT Study Group. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. *J Clin Oncol* 2006, 24:1800-1806.

de Jong WK, Ten Hacken NH, Groen HJ. Third-line chemotherapy for small cell lung cancer. *Lung Cancer*, 2006, 52:339-342.

Westerman M, Hak T, The AM, Groen H, van der Wal G. Problems eliciting cues in SEIQoL-DW: quality of life areas in small-cell lung cancer patients. *Qual Life Res*, 2006, 15:441-449.

Kramer H, Post WJ, Pruim J, Groen HJM. The prognostic value of positron emission tomography in non-small-cell lung cancer: analysis of 266 cases. *Lung Cancer*, 2006, 52:213-217.

Fokkema E, Timens W, de Vries EG, de Jong S, Fidler V, Meijer C, Groen HJ. Expression and prognostic implications of apoptosis-related proteins in locally unresectable non-small cell lung cancers. *Lung Cancer*, 2006, 52:241-247.

Auperin A, Le Pechoux C, Pignon JP, Koning C, Jeremic B, Clamon G, Einhorn L, Ball D, Trovo MG, Groen HJ, Bonner JA, Le Chevalier T, Arriagada R; Meta-Analysis of Cisplatin/carboplatin based Concomitant Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. *Ann Oncol*, 2006, 17:473-483.

Boelens MC, van den Berg A, Vogelzang I, Wesseling J, Postma DS, Timens W, Groen HJ. Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus. *J Clin Path*, 2006, 17,

Uyl-de Groot CA, McDonnell J, Ten Velde G, Radice D, Groen HJ. Cost-effectiveness of hypothetical new cancer drugs in patients with advanced small-cell lung cancer: results of a markov chain model. *Ther Clin Risk Manag*. 2006 Sep;2(3):317-23.

de Groot DJ, de Vries EG, Groen HJ, de Jong S. Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. *Crit Rev Oncol Hematol*. 2007 Jan;61(1):52-69. Epub 2006 Sep 1. Review. PMID: 16945549

Gietema JA, Hoekstra R, de Vos FY, Uges DR, van der Gaast A, Groen HJ, Loos WJ, Knight RA, Carr RA, Humerickhouse RA, Eskens FA. A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. *Ann Oncol*. 2006 Aug;17(8):1320-7.

Kramer H, Sanders J, Post WJ, Groen HJ, Suurmeijer AJ. Analysis of cytological specimens from mediastinal lesions obtained by endoscopic ultrasound-guided fine-needle aspiration. *Cancer*. 2006 Aug 25;108(4):206-11

Stokman MA, Oude Nijhuis CS, Spijkervet FK, de Bont ES, Dijkstra PU, Daenen SM, Gietema JA, van der Graaf WT, Groen HJ, Vellenga E, Kamps WA. The role of oral mucositis on the systemic inflammation parameter IL-8 in febrile neutropenic cancer patients. *Cancer Invest*. 2006 Aug-Sep;24(5):479-83.

Hermens RP, Ouwens MM, Vonk-Okhuijsen SY, van der Wel Y, Tjan-Heijnen VC, van den Broek LD, Ho VK, Janssen-Heijnen ML, Groen HJ, Grol RP, Wollersheim HC. Development of quality indicators for diagnosis and treatment of patients with non-small cell lung cancer: a first step toward implementing a multidisciplinary, evidence-based guideline. *Lung Cancer*. 2006 Oct;54(1):117-24.

de Jong WK, Fidler V, Groen HJ. Prognostic classification with laboratory parameters or imaging techniques in small-cell lung cancer. *Clin Lung Cancer*. 2007 May;8(6):376-81

Westerman MJ, The AM, Sprangers MA, Groen HJ, van der Wal G, Hak T. Small-cell lung cancer patients are just 'a little bit' tired: response shift and self-presentation in the measurement of fatigue. *Qual Life Res*. 2007 Jun;16(5):853-61.

Bart J, Nagengast WB, Coppes RP, Wegman TD, van der Graaf WT, Groen HJ, Vaalburg W, de Vries EG, Hendrikse NH. Irradiation of rat brain reduces P-glycoprotein expression and function. *Br J Cancer*. 2007 Aug 6;97(3):322-6.

Boelens MC, te Meerman GJ, Gibcus JH, Blokzijl T, Boezen HM, Timens W, Postma DS, Groen HJ, van den Berg A. Microarray amplification bias: loss of 30% differentially expressed genes due to long probe - poly(A)-tail distances. *BMC Genomics*. 2007 Aug 15;8:277.

Westerman MJ, Hak T, The AM, Echteid MA, Groen HJ, van der Wal G. Change in what matters to palliative patients: eliciting information about adaptation with SEIQoL-DW. *Palliat Med*. 2007 Oct;21(7):581-6.

de Jong WK, Groen HJ, Koolen MG, Biesma B, Willems LN, Kwa HB, van Bochove A, van Tinteren H, Smit EF. Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer. *Eur J Cancer*. 2007 Nov;43(16):2345-50.

de Jong WK, van der Heijden HF, Pruim J, Dalesio O, Oyen WJ, Groen HJ. Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center study. *J Thorac Oncol*. 2007 Nov;2(11):1007-12.

de Jong WK, de Jonge MJ, van der Leest AH, van Meerbeeck JP, Groen HJ. Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: A phase I study. *Lung Cancer*. 2008 Jan 5.

de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. *Eur J Cancer*. 2008 Jan;44(1):123-30.

Kappers I, Belderbos JS, Burgers JA, van Zandwijk N, Groen HJ, Klomp HM. Non-small cell lung carcinoma of the superior sulcus: favourable outcomes of combined modality treatment in carefully selected patients. *Lung Cancer*. 2008 Mar;59(3):385-90.

Westerman MJ, Hak T, Sprangers MA, Groen HJ, van der Wal G, The AM. Listen to their answers! Response behaviour in the measurement of physical and role functioning. *Qual Life Res*. 2008 Apr 4.

de Jong WK, Schaapveld M, Blaauwgeers JL, Groen HJ. Pulmonary tumours in the Netherlands: focus on temporal trends in histology and stage and on rare tumours. *Thorax*. 2008 Dec;63(12):1096-102. Epub 2008 Aug 4.

Groen HJ. Prophylactic cranial irradiation: a new standard for all responding patients with small cell lung cancer. *Ned Tijdschr Geneeskd*. 2008

Westerman MJ, Hak T, Sprangers MA, Groen HJ, van der Wal G, The AM. Listen to their answers! Response behaviour in the measurement of physical and role functioning. *Qual Life Res*. 2008 May;17(4):549-58.

El Sharouni SY, Aerts JG, Senan S, De Ruyscher DK, Groen HJ, Paul MA, Smit EF, Vonk EJ, Verhagen AF, Schramel FM. Treatment of patients with stage III non-small cell lung cancer: concurrent high-dose chemotherapy and radiotherapy. *Ned Tijdschr Geneeskd*. 2008 Dec 13;152(50):2714-7.

Boelens MC, van den Berg A, Fehrmann RS, Geerlings M, de Jong WK, Te Meerman GJ, Sietsma H, Timens W, Postma DS, Groen HJ. Current smoking-specific gene expression signature in normal bronchial epithelium is enhanced in squamous cell lung cancer. *J Pathol*. 2009 Jan 13;218(2):182-191.

De Jong WK, Verpooten GF, Kramer H, Louwagie J, Groen HJ. Promoter methylation primarily occurs in tumor cells of patients with non-small cell lung cancer. *Anticancer Res*. 2009 Jan;29(1):363-9.

Stigt JA, Oostdijk AH, Timmer PR, Shahin GM, Boers JE, Groen HJ. Comparison of EUS-guided fine needle aspiration and integrated PET-CT in restaging after treatment for locally advanced non-small cell lung cancer. *Lung Cancer*. 2009 Feb 19.

Boelens MC, Kok K, van der Vlies P, van der Vries G, Sietsma H, Timens W, Postma DS, Groen HJ, van den Berg A. Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. *Lung Cancer*. 2009 Mar 24.

Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. *J Clin Oncol*. 2009 Apr 20;27(12):2038-45. Epub 2009 Mar 23.

Boelens MC, van den Berg A, Fehrmann RS, Geerlings M, de Jong WK, te Meerman GJ, Sietsma H, Timens W, Postma DS, Groen HJ. Current smoking-specific gene expression signature in normal bronchial epithelium is enhanced in squamous cell lung cancer.

J Pathol. 2009 Jun;218(2):182-91.

Coenen MJ, Trynka G, Heskamp S, Franke B, van Diemen CC, Smolonska J, van Leeuwen M, Brouwer E, Boezen MH, Postma DS, Platteel M, Zanen P, Lammers JW, Groen HJ, Mali WP, Mulder CJ, Tack GJ, Verbeek WH, Wolters VM, Houwen RH, Mearin ML, van Heel DA, Radstake TR, van Riel PL, Wijmenga C, Barrera P, Zhernakova A. Common and different genetic background for rheumatoid arthritis and coeliac disease. *Hum Mol Genet.* 2009 Nov 1;18(21):4195-203. Epub 2009 Jul 31.

van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, Vernhout R, van Iersel CA, van den Bergh KA, van 't Westeinde S, van der Aalst C, Thunnissen E, Xu DM, Wang Y, Zhao Y, Gietema HA, de Hoop BJ, Groen HJ, de Bock GH, van Ooijen P, Weenink C, Verschakelen J, Lammers JW, Timens W, Willebrand D, Vink A, Mali W, de Koning HJ.

Management of lung nodules detected by volume CT scanning.

N Engl J Med. 2009 Dec 3;361(23):2221-9.

Lambrechts D, Buyschaert I, Zanen P, Coolen J, Lays N, Cuppens H, Groen HJ, Dewever W, van Klaveren RJ, Verschakelen J, Wijmenga C, Postma DS, Decramer M, Janssens W.

The 15q24/25 susceptibility variant for lung cancer and chronic obstructive pulmonary disease is associated with emphysema. *Am J Respir Crit Care Med.* 2010 Mar 1;181(5):486-93. Epub 2009 Dec 10.

Stegehuis JH, de Wilt LH, de Vries EG, Groen HJ, de Jong S, Kruyt FA

TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. *Drug Resist Updat.* 2010 Feb-Apr;13(1-2):2-15. Epub 2009 Dec 29

Dubois PC, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, Zhernakova A, Heap GA, Adany R, Aromaa A, Bardella MT, van den Berg LH, Bockett NA, de la Concha EG, Dema B, Fehrmann RS, Fernandez-Arquero M, Fiatal S, Grandone E, Green PM, Groen HJ, Gwilliam R, Houwen RH, Hunt SE, Kaukinen K, Kelleher D, Korponay-Szabo I, Kurppa K, MacMathuna P, Maki M, Mazzilli MC, McCann OT, Mearin ML, Mein CA, Mirza MM, Mistry V, Mora B, Morley KI, Mulder CJ, Murray JA, Nunez C, Oosterom E, Ophoff RA, Polanco I, Peltonen L, Platteel M, Rybak A, Salomaa V, Schweizer JJ, Sperandio MP, Tack GJ, Turner G, Veldink JH, Verbeek WH, Weersma RK, Wolters VM, Urcelay E, Cukrowska B, Greco L, Neuhausen SL, McManus R, Barisani D, Deloukas P, Barrett JC, Saavalainen P, Wijmenga C, van Heel DA.

Multiple common variants for celiac disease influencing immune gene expression. *Nat Genet.* 2010 Apr;42(4):295-302. Epub 2010 Feb 28

Maring JG, Wachters FM, Slijfer M, Maurer JM, Boezen HM, Uges DR, de Vries EG, Groen HJ. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. *Eur J Clin Pharmacol.* 2010 Mar 6

Maring JG, Wachters FM, Maurer M, Uges DR, de Vries EG, Groen HJ. Gemcitabine and Epirubicin Plasma Concentration-Related Excretion in Saliva in Patients With Non-Small Cell Lung Cancer. *Ther Drug Monit.* 2010 Mar 23.

Lind JS, Dingemans AM, Groen HJ, Thunnissen E, Bekers O, Heideman DA, Honeywell R, Giovannetti E, Peters GJ, Postmus PE, van Suylen RJ, Smit EF.

A Multicenter, Phase II study of Erlotinib and Sorafenib in Chemotherapy-naive Patients with Advanced Non-Small Cell Lung Cancer. *Clin Cancer Res.* 2010 Apr 15.

Navani N, Nankivell M, Stephens RJ, Parmar MK, Gilligan D, Nicolson M, Groen HJ, van Meerbeeck JP.

Inaccurate clinical nodal staging of non-small cell lung cancer: evidence from the MRC LU22 multicentre randomised trial. *Thorax.* 2010 May;65(5):463.

Dingemans AM, de Langen AJ, van den Boogaart V, Marcus JT, Backes WH, Scholtens HT, van Tinteren H, Hoekstra OS, Pruim J, Brans B, Thunnissen FB, Smit EF, Groen HJ.

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. *Ann Oncol.* 2010 Aug 11.

Boelens MC, Gustafson AM, Postma DS, Kok K, van der Vries G, van der Vlies P, Spira A, Lenburg ME, Geerlings M, Sietsma H, Timens W, van den Berg A, Groen HJ.

A chronic obstructive pulmonary disease related signature in squamous cell lung cancer. *Lung Cancer.* 2010 Sep 9.

Janssen-Heijnen ML, Maas HA, van de Schans SA, Coebergh JW, Groen HJ.

Chemotherapy in elderly small-cell lung cancer patients: yes we can, but should we do it?

Ann Oncol. 2010 Oct 7.

Maas KW, El Sharouni SY, Phernambucq EC, Stigt JA, Groen HJ, Herder GJ, Van Den Borne BE, Senan S, Paul MA, Smit EF, Schramel FM.

Weekly chemoradiation (docetaxel/cisplatin) followed by surgery in stage III NSCLC; a multicentre phase II study.

Anticancer Res. 2010 Oct;30(10):4237-43.

de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, Pruijm J, Brans B, Leffers P, Dingemans AM, Smit EF, Groen HJ, Hoekstra OS.

Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI.

J Nucl Med. 2011 Jan;52(1):48-55. Epub 2010 Dec 13.

Wiegman EM, Pruijm J, Ubbels JF, Groen HJ, Langendijk JA, Widder J.

F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study.

Eur J Nucl Med Mol Imaging. 2011 Jan 6.

Jaspers GW, Witjes MJ, Groen HJ, Groen H, Rodiger LA, Roodenburg JL.

Strategies for patients with newly diagnosed oral squamous cell carcinoma and a positive chest CT. A cohort study on the effects on treatment planning and incidence.

Eur J Surg Oncol. 2011 Mar;37(3):272-7. Epub 2011 Jan 12.

Biesma B, Wymenga AN, Vincent A, Dalesio O, Smit HJ, Stigt JA, Smit EF, van Felius CL, van Putten JW, Slaets JP, Groen HJ; on behalf of the Dutch Chest Physician Study Group.

Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncol. 2011 Feb 8.

Janse M, Lamberts LE, Franke L, Raychaudhuri S, Ellinghaus E, Muri Boberg K, Melum E, Folseraas T, Schrupf E, Bergquist A, Bjornsson E, Fu J, Jan Westra H, Groen HJ, Fehrmann RS, Smolonska J, van den Berg LH, Ophoff RA, Porte RJ, Weismuller TJ, Wedemeyer J, Schramm C, Sterneck M, Gunther R, Braun F, Vermeire S, Henckaerts L, Wijmenga C, Ponsioen CY, Schreiber S, Karlsen TH, Franke A, Weersma RK.

Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9.

Hepatology. 2011 Jun;53(6):1977-85. doi: 10.1002/hep.24307. Epub 2011 May 2.

Mohamed Hoesein FA, de Hoop B, Zanen P, Gietema H, Kruitwagen CL, van Ginneken B, Isgum I, Mol C, van Klaveren RJ, Dijkstra AE, Groen HJ, Boezen HM, Postma DS, Prokop M, Lammers JW. CT-quantified emphysema in male heavy smokers: association with lung function decline. Thorax. 2011 Apr 7.

Stigt JA, Boers JE, Oostdijk AH, van den Berg JW, Groen HJ.

Mediastinal Incidentalomas. J Thorac Oncol. 2011 May 16

Janssen-Heijnen ML, Maas HA, Siesling S, Koning CC, Coebergh JW, Groen HJ.

1. Treatment and survival of patients with small-cell lung cancer: small steps forward, but not for patients >80. Ann Oncol. 2011 Jun 20

Fehrmann RS, Jansen RC, Veldink JH, Westra HJ, Arends D, Bonder MJ, Fu J, Deelen P, Groen HJ, Smolonska A, Weersma RK, Hofstra RM, Buurman WA, Rensen S, Wolfs MG, Platteel M, Zhernakova A, Elbers CC, Festen EM, Trynka G, Hofker MH, Saris CG, Ophoff RA, van den Berg LH, van Heel DA, Wijmenga C, Te Meerman GJ, Franke L.

Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA.

PLoS Genet. 2011 Aug;7(8):e1002197. Epub 2011 Aug 4.

Van t Westeinde SC, de Koning HJ, Thunnissen FB, Oudkerk M, Groen HJ, Lammers JW, Weenink C, Vernhout R, Nackaerts K, Mali W, van Klaveren RJ.

The Role of the (18)F-Fluorodeoxyglucose-Positron Emission Tomography Scan in the Netherlands Levens Longkanker Screenings Onderzoek Lung Cancer Screening Trial.

J Thorac Oncol. 2011 Oct;6(10):1704-1712.

Stigt JA, Oostdijk AH, Boers JE, van den Berg JW, Groen HJ.

Percutaneous Ultrasound-Guided Biopsies in the Evaluation of Thoracic Tumours after PET-CT: A Prospective Diagnostic Study.

Respiration. 2011 Sep 16.

Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM.

Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.

J Clin Oncol. 2011 Nov 10;29(32):4320-6.

Groen HJ, Hiltermann TJ, Schuurin E, Timens W.

New 'targeted therapy' for lung cancer].

Ned Tijdschr Geneeskd. 2011;155(45):A4081. Dutch.

van der Drift MA, Karim-Kos HE, Siesling S, Groen HJ, Wouters MW, Coebergh JW, de Vries E, Janssen-Heijnen ML.

Progress in Standard of Care Therapy and Modest Survival Benefits in the Treatment of Non-small Cell Lung Cancer Patients in the Netherlands in the Last 20 Years.

J Thorac Oncol. 2011 Dec 7.

Janssen-Heijnen ML, Karim-Kos HE, Drift MA, Groen HJ, Ho VK, Koning C, de Vries E; On behalf of the Working Group Output of the Netherlands Cancer Registry.

Modest Improvements of Survival for Patients with Small Cell Lung Cancer Aged 45 to 59 Years Only, Diagnosed in the Netherlands, 1989 to 2008.

J Thorac Oncol. 2012 Jan;7(1):227-232.

Stigt JA, Wolfhagen MJ, Boomsma MF, Mostert AK, Groen HJ.

Diagnosing infectious spondylodiscitis with endoscopic ultrasound.

J Bronchology Interv Pulmonol. 2012 Jan;19(1):82-4. doi: 10.1097/LBR.0b013e3182446924.

Fu J, Wolfs MG, Deelen P, Westra HJ, Fehrmann RS, Te Meerman GJ, Buurman WA, Rensen SS, Groen HJ, Weersma RK, van den Berg LH, Veldink J, Ophoff RA, Snieder H, van Heel D, Jansen RC, Hofker MH, Wijmenga C, Franke L.

Unraveling the regulatory mechanisms underlying tissue-dependent genetic variation of gene expression.

PLoS Genet. 2012 Jan;8(1):e1002431. Epub 2012 Jan 19.

van 't Westeinde SC, Horeweg N, Vernhout RM, Groen HJ, Lammers JW, Weenink C, Nackaerts K, Oudkerk M, Mali W, Thunnissen FB, de Koning HJ, van Klaveren RJ.

The role of conventional bronchoscopy in the work-up of suspicious CT screen detected pulmonary nodules.

Chest. 2012 Feb 2.

Janssen-Heijnen ML, van Steenbergen LN, Steyerberg E, Visser O, De Ruyscher DK, Groen HJ.

Long-Term Excess Mortality for Survivors of Non-small Cell Lung Cancer in the Netherlands.

J Thorac Oncol. 2012 Mar;7(3):496-502.

Stigt JA, Uil SM, Oostdijk AH, Boers JE, van den Berg JW, Groen HJ.

A Diagnostic Program for Patients Suspected of Having Lung Cancer.

Clin Lung Cancer. 2012 Apr 10.

Hiltermann TJ, Pore MM, van den Berg A, Timens W, Boezen HM, Liesker JJ, Schouwink JH, Wijnands WJ, Kerner GS, Kruyt FA, Tissing H, Tibbe AG, Terstappen LW, Groen HJ.

Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor.

Ann Oncol. 2012 Jun 11.

Mohamed Hoesein FA, Zanen P, Boezen HM, Groen HJ, van Ginneken B, de Jong PA, Postma DS, Lammers JW.

Lung function decline in heavy male smokers relates to baseline airflow obstruction severity.

Chest. 2012 Jun 21.

van 't Westeinde SC, Horeweg N, Vernhout RM, Groen HJ, Lammers JW, Weenink C, Nackaerts K, Oudkerk M, Mali W, Thunnissen FB, de Koning HJ, van Klaveren RJ.

The role of conventional bronchoscopy in the workup of suspicious CT scan screen-detected pulmonary nodules.

Chest. 2012 Aug;142(2):377-84.

Blumenschein GR Jr, Ciuleanu T, Robert F, Groen HJ, Usari T, Ruiz-Garcia A, Tye L, Chao RC, Juhasz E.

Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.

J Thorac Oncol. 2012 Sep;7(9):1406-16.

Stigt JA, Boers JE, Groen HJ.

Analysis of "dry" mesothelioma with ultrasound guided biopsies.

Lung Cancer. 2012 Sep 25. pii: S0169-5002(12)00528-4. doi: 10.1016/j.lungcan.2012.09.004.

Horeweg N, van Klaveren RJ, Groen HJ, Lammers JW, Weenink C, Nackaerts K, Mali W, Oudkerk M, de Koning HJ.

Blinded and uniform cause of death verification in a lung cancer CT screening trial.

Lung Cancer. 2012 Sep;77(3):522-5.

Van't Westeinde SC, Horeweg N, De Leyn P, Groen HJ, Lammers JW, Weenink C, Nackaerts K, van Klaveren RJ.

Complications following lung surgery in the Dutch-Belgian randomized lung cancer screening trial.

Eur J Cardiothorac Surg. 2012 Sep;42(3):420-9.

Hiltermann TJ, van der Wekken AJ, Groen HJ.

Moving forward with circulating tumor cells and lung cancer.

J Thorac Dis. 2012 Oct;4(5):440-1. doi: 10.3978/j.issn.2072-1439.2012.08.08.

Bollineni VR, Wiegman EM, Pruijm J, Groen HJ, Langendijk JA

Hypoxia imaging using Positron Emission Tomography in non-small cell lung cancer: Implications for radiotherapy.

Cancer Treat Rev. 2012 Dec;38(8):1027-32. doi: 10.1016/j.ctrv.2012.04.003.

van 't Westeinde SC, Horeweg N, Vernhout RM, Groen HJ, Lammers JW, Weenink C, Nackaerts K, Oudkerk M, Mali W, Thunnissen FB, de Koning HJ, van Klaveren RJ.

The role of conventional bronchoscopy in the workup of suspicious CT scan screen-detected pulmonary nodules.

Chest. 2012 Aug;142(2):377-84.

Stigt JA, Wolfhagen MJ, Boomsma MF, Mostert AK, Groen HJ.

Diagnosing infectious spondylodiscitis with endoscopic ultrasound.

J Bronchology Interv Pulmonol. 2012 Jan;19(1):82-4. doi: 10.1097/LBR.0b013e3182446924.

Stigt JA, Uil SM, van Riesen SJ, Simons FJ, Denekamp M, Shahin GM, Groen HJ.

A Randomized Controlled Trial of Postthoracotomy Pulmonary Rehabilitation in Patients with Resectable Lung Cancer.

J Thorac Oncol. 2012 Dec 12. [Epub ahead of print]

Dingemans AM, Mellema WW, Groen HJ, Van Wijk A, Burgers SA, Kunst PW, Thunnissen E, Heideman DA, Smit EF.

.A phase II study of sorafenib in patients with platinum pretreated, advanced (stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.

Clin Cancer Res. 2012 Dec 6. [Epub ahead of print]

van Geffen WH, Hiltermann TJ, Groen HJ.

Surviving Respiratory Insufficiency with Intensive Care Support in a Pretreated, Extensively Metastasized Patient with an EML4-ALK Translocation.

J Thorac Oncol. 2013 Jan;8(1):e1-2.

Dijkstra AE, Postma DS, Ten Hacken N, Vonk JM, Oudkerk M, van Ooijen PM, Zanen P, Mohamed Hoesein FA, van Ginneken B, Schmidt M, Groen HJ

Low-dose CT measurements of airway dimensions and emphysema associated with airflow limitation in heavy smokers: a cross sectional study. .

Respir Res. 2013 Jan 28;14(1):11.

Zanen P, Groen HJ, Marika Boezen H, Postma DS, Wijmenga C, Viergever MA, Mali WP, de Bakker PI. Genome-wide association study of coronary and aortic calcification implicates risk loci for coronary artery disease and myocardial infarction. van Setten J, Isgum I, Smolonska J, Ripke S, de Jong PA, Oudkerk M, de Koning H, Lammers JW,

Atherosclerosis. 2013 Mar 13. doi:pii: S0021-9150(13)00175-5. 10.1016/j.atherosclerosis.2013.02.039.

Heuvelmans MA, Oudkerk M, de Bock GH, de Koning HJ, Xie X, van Ooijen PM, Greuter MJ, de Jong PA, Groen HJ, Vliegenthart R.

Optimisation of volume-doubling time cutoff for fast-growing lung nodules in CT lung cancer screening reduces false-positive referrals. *Eur Radiol.* 2013 Mar 19.

Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF, Baas P.

Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. *Lancet Oncol.* 2013 Apr 11. doi:pii: S1470-2045(13)70125-6. 10.1016/S1470-2045(13)70125-6

Mohamed Hoesein FA, Zanen P, de Jong PA, van Ginneken B, Boezen HM, Groen HJ, Oudkerk M, de Koning HJ, Postma DS, Lammers JW.

Rate of progression of CT-quantified emphysema in male current and ex-smokers: a follow-up study. *Respir Res.* 2013 May 20;14(1):55.

Bollineni VR, Kerner GS, Pruijm J, Steenbakkens RJ, Wiegman EM, Koole MJ, de Groot EH, Willemsen AT, Luurtsema G, Widder J, Groen HJ, Langendijk JA.

PET Imaging of Tumor Hypoxia Using 18F-Fluoroazomycin Arabinoside in Stage III-IV Non-Small Cell Lung Cancer Patients. *Nucl Med.* 2013 Jun 10

Ciuleanu T, Tsai CM, Tsao CJ, Milanowski J, Amoroso D, Heo DS, Groen HJ, Szczesna A, Chung CY, Chao TY, Middleton G, Zeaiter A, Klingelschmitt G, Klughammer B, Thatcher N.

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.

Lung Cancer. 2013 Aug 13. doi:pii: S0169-5002(13)00357-7. 10.1016/j.lungcan.2013.08.002.

Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Kim JH, Ahn MJ, Aerts JG, Vikstrom A, Groen HJ. Reply to B.M. Strebel.

J Clin Oncol. 2013 Dec 30.

Gerald S. M. A. Kerner, Ed Schuurin, Johanna Sietsma, Thijo J. N. Hiltermann, Remge M. Pieterman, Gerard P. J. de Leede, John W. G. van Putten, Jeroen Liesker, Tineke E. J. Renkema, Peter van Hengel, Inge Platteel, Wim Timens, Harry J. M. Groen, on behalf of the CTMM Air Force Consortium. Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population

and Their Clinical Outcome. *PloS ONE* 8(7):e70346. doi:10.1371/journal.pone.0070346

Manichaikul A, Hoffman EA, Smolonska J, Gao W, Cho MH, Baumhauer H, Budoff M, Austin JH, Washko GR, Carr JJ, Kaufman JD, Pottinger T, Powell CA, Wijmenga C, Zanen P, Groen HJ, Postma DS, Wanner A, Rouhani FN, Brantly ML, Powell R, Smith BM, Rabinowitz D, Raffel LJ, Hinckley Stukovsky KD, Crapo JD, Beaty TH, Hokanson JE, Silverman EK, Dupuis J, O'Connor GT, Boezen HM, Rich SS, Barr RG

Genome-wide Study of Percent Emphysema on CT in the General Population: The MESA Lung/SHARe Study. *Am J Respir Crit Care Med.* 2014 Jan 2.

Janssen-Heijnen ML, Maas HA, Koning CC, van der Bruggen-Bogaarts BA, Groen HJ, Wymenga AN.

Takx RA, Vliegenthart R, Hoesein FA, Isgum I, de Koning HJ, Mali WP, van der Aalst CM, Zanen P, Lammers JW, Groen HJ, van Rikxoort EM, Schmidt M, van Ginneken B, Oudkerk M, Leiner T, de Pulmonary function and CT biomarkers as risk factors for cardiovascular events in male lung cancer screening participants: the NELSON study. *Jong PA. Eur Radiol.* 2014 Sep 3.

Kerner GS, van Dulleme LF, Wiegman EM, Widder J, Blokzijl E, Driever EM, van Putten JW, Liesker JJ, Renkema TE, Pieterman RM, Mertens MJ, Hiltermann TJ, Groen HJ.

Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer.

Xie X, Dijkstra AE, Vonk JM, Oudkerk M, Vliegenthart R, Groen HJ.

Chronic Respiratory Symptoms Associated With Airway Wall Thickening Measured by Thin-Slice Low-Dose CT.

AJR Am J Roentgenol. 2014 Oct;203(4):W383-90. doi: 10.2214/AJR.13.11536.

Horeweg N, van Rosmalen J, Heuvelmans MA, van der Aalst CM, Vliegenthart R, Th Scholten E, Ten Haaf K, Nackaerts K, Lammers JW, Weenink C, Groen HJ, van Ooijen P, de Jong PA, de Bock GH, Mali W, de Koning HJ, Oudkerk M.

Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening.

Lancet Oncol. 2014 Oct 1. pii: S1470-2045(14)70389-4. doi: 10.1016/S1470-2045(14)70389-4.

Heuvelmans MA, Oudkerk M, de Jong PA, Mali WP, Groen HJ, Vliegenthart R

The impact of radiologists' expertise on screen results decisions in a CT lung cancer screening trial.

Eur Radiol. 2014 Nov 4. [

Scholten ET, de Jong PA, de Hoop B, van Klaveren R, van Amelsvoort-van de Vorst S, Oudkerk M, Vliegenthart R, de Koning HJ, van der Aalst CM, Vernhout RM, Groen HJ, Lammers JW, van Ginneken B, Jacobs C, Mali WP, Horeweg N, Weenink C, Thunnissen E, Prokop M, Gietema HA.

Towards a close computed tomography monitoring approach for screen detected subsolid pulmonary nodules?

Eur Respir J. 2014 Nov 27. pii: erj00059-2014.

Dijkstra AE, Postma DS, van Ginneken B, Wielputz MO, Schmidt M, Becker N, Owsijewitsch M, Kauczor HU, de Koning HJ, Lammers JW, Oudkerk M, Brandsma CA, Bosse Y, Nickle DC, Sin DD, Hiemstra PS, Wijmenga C, Smolonska J, Zanen P, Vonk JM, van den Berge M, Boezen HM, Groen HJ.

Novel Genes for Airway Wall Thickness Identified with Combined Genome Wide Association and Expression Analyses. Am J Respir Crit Care Med . 2014 Dec 17.

Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpre P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J.

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus.

Lung Cancer. 2014 Dec 18. pii: S0169-5002(14)00520-0. doi: 10.1016/j.lungcan.2014.12.010

Mohamed Hoesein FA, de Jong PA, Lammers JW, Mali WP, Schmidt M, de Koning HJ, van der Aalst C, Oudkerk M, Vliegenthart R, Groen HJ, van Ginneken B, van Rikxoort EM, Zanen P.

Airway wall thickness associated with forced expiratory volume in 1 second decline and development of airflow limitation. Eur Respir J. 2015 Jan 22.

van den Berg LL, Klinkenberg TJ, Groen HJ, Widder J. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC J Thorac Oncol. 2015 Jan 27.

Janssen-Heijnen ML, van Erning FN, De Ruyscher DK, Coebergh JW, Groen HJ

Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol. 2015 Feb 11. pii: mdv061.

van der Wekken AJ, Hiltermann TJ, Groen HJ.

The value of proteomics in lung cancer. Ann Transl Med. 2015 Mar;3(3):29. doi: 10.3978/j.issn.2305-5839.2015.01.10.

Kerner GS, Fischer A, Koole MJ, Pruijm J, Groen HJ.

Evaluation of elastix-based propagated align algorithm for VOI- and voxel-based analysis of longitudinal (18)F-FDG PET/CT data from patients with non-small cell lung cancer (NSCLC). EJNMMI Res. 2015 Mar 21;5:15. doi: 10.1186/s13550-015-0089-z. eCollection 2015.

Niezink AG, Dollekamp NJ, Elzinga HJ, Borger D, Boer EJ, Ubbels JF, Woltman-van Iersel M, van der Leest AH, Beijert M, Groen HJ, Kraan J, Hiltermann TJ, van der Wekken AJ, van Putten JW, Rutgers SR, Pieterman RM, de Hosson SM, Roenhorst AW, Langendijk JA, Widder J.

An instrument dedicated for modelling of pulmonary radiotherapy

Radiother Oncol. 2015 Apr 9. pii: S0167-8140(15)00159-0. doi: 10.1016/j.radonc.2015.03.020.

Groen HJ. Treatment of lung cancer guided by genomic tumour profiles. Ned Tijdschr Geneeskd. 2015;159(0):A9029. Dutch.

Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, van den Borne BE, Munsell MF, Hurkmans C, Berry DA, van Werkhoven E, Kresl JJ, Dingemans AM, Dawood O, Haasbeek CJ, Carpenter LS, De Jaeger K, Komaki R, Slotman BJ, Smit EF, Roth JA.

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Lancet Oncol . 2015 May 13. pii: S1470-2045(15)70168-3. doi: 10.1016/S1470-2045(15)70168-3

Dijkstra AE, Smolonska J, van den Berge M, Wijmenga C, Zanen P, Luinge MA, Platteel M, Lammers JW, Dahlback M, Tosh K, Hiemstra PS, Sterk PJ, Spira A, Vestbo J, Nordestgaard BG, Benn M, Nielsen SF, Dahl M, Verschuren WM, Picavet HS, Smit HA, Owsijewitsch M, Kauczor HU, de Koning HJ, Nizankowska-Mogilnicka E, Mejza F, Nastalek P, van Diemen CC, Cho MH, Silverman EK, Crapo JD, Beaty TH, Lomas DA, Bakke P, Gulsvik A, Bosse Y, Obeidat M, Loth DW, Lahousse L, Rivadeneira F, Uitterlinden AG, Hofman A, Stricker BH, Brusselle GG, van Duijn CM, Brouwer U, Koppelman GH, Vonk JM, Nawijn MC, Groen HJ, Timens W, Boezen HM, Postma DS; LifeLines Cohort study

Correction: Susceptibility to Chronic Mucus Hypersecretion, a Genome Wide Association Study. .

PLoS One. 2015 May 29;10(5):e0129524. doi: 10.1371/journal.pone.0129524. eCollection 2015.

de Goeje PL, Bezemer K, Heuvers ME, Dingemans AC, Groen HJ, Smit EF, Hoogsteden HC, Hendriks RW, Aerts JG, Hegmans JP. Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer. *Oncoimmunology*. 2015 Mar 19;4(7):e1014242. eCollection 2015 Jul.

Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, Thunnissen E, Heideman DA, Berk Y, Buijs EJ, Speel EM, Krouwels FH, Smit HJ, Groen HJ, Dingemans AC, Smit EF. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. *Lung Cancer*. 2015 Jun 6. pii: S0169-5002(15)00284-6. doi: 10.1016/j.lungcan.2015.05.023.

Wit S, Dalum GV, Lenferink AT, Tibbe AG, Hiltermann TJ, Groen HJ, van Rijn CJ, Terstappen LW. The detection of EpCAM and EpCAM circulating tumor cells. *Sci Rep*. 2015 Jul 17;5:12270. doi: 10.1038/srep12270.

Dingemans AC, Groen HJ, Herder GJ, Stigt JA, Smit EF, Bahce I, Burgers JA, van den Borne BE, Biesma B, Vincent A, van der Noort V, Aerts JG; NVALT study group. A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV non-squamous-non-small cell lung cancer: NVALT 12 (NCT01171170).

Ann Oncol. 2015 Sep 7. pii: mdv370.

Clausen MJ, Melchers LJ, Mastik MF, Slagter-Menkema L, Groen HJ, van der Laan BF, van Criekinge W, de Meyer T, Denil S, Wisman GB, Roodenburg JL, Schuurig E.

Identification and validation of WISP1 as an epigenetic regulator of metastasis in oral squamous cell carcinoma. *Genes Chromosomes Cancer*. 2015 Sep 22. doi: 10.1002/gcc.22310.

Louie AV, van Werkhoven E, Chen H, Smit EF, Paul MA, Widder J, Groen HJ, van den Borne BE, De Jaeger K, Slotman BJ, Senan S.

Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial. *Radiother Oncol*. 2015 Oct;117(1):44-8. doi: 10.1016/j.radonc.2015.08.011.

Derks JL, Hendriks LE, Buikhuisen WA, Groen HJ, Thunnissen E, van Suylen RJ, Houben R, Damhuis RA, Speel EJ, Dingemans AC.

Clinical features of large cell neuroendocrine carcinoma: a population-based overview.

Eur Respir J. 2015 Nov 5. pii: ERJ-00618-2015. doi: 10.1183/13993003.00618-2015

van der Linden N, Bongers ML, Coupe VM, Smit EF, Groen HJ, Welling A, Schramel FM, Uyl-de Groot CA Costs of non-small cell lung cancer in the Netherlands. *Lung Cancer*. 2015 Oct 17. pii: S0169-5002(15)30084-2. doi: 10.1016/j.lungcan.2015.10.015.

Derks JL, van Suylen RJ, Thunnissen E, den Bakker MA, Smit EF, Groen HJ, Speel EJ, Dingemans AC

A population based analysis on application of WHO-nomenclature in pathology reports of pulmonary neuroendocrine tumors. *J Thorac Oncol*. 2016 Jan 8. pii: S1556-0864(16)00282-3. doi: 10.1016/j.jtho.2015.12.106.

van der Wekken AJ, Saber A, Hiltermann TJ, Kok K, van den Berg A, Groen HJ.

Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature.

Crit Rev Oncol Hematol. 2016 Jan 25. pii: S1040-8428(16)30024-5. doi: 10.1016/j.critrevonc.2016.01.024.

van den Boogaart VE, de Lussanet QG, Houben RM, de Ruyscher D, Groen HJ, Marcus JT, Smit EF, Dingemans AM, Backes WH

Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinib. .

Lung Cancer. 2016 Mar;93:20-7. doi: 10.1016/j.lungcan.2015.12.009.

Saber A, van der Wekken AJ, Kerner GS, van den Berge M, Timens W, Schuurung E, Ter Elst A, van den Berg A, Hiltermann TJ, Groen HJ

Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer. PLoS One. 2016 Mar 23;11(3):e0152317. doi: 10.1371/journal.pone.0152317. eCollection 2016.

van Kruijsdijk RC, Visseren FL, Boni L, Groen HJ, Dingemans AM, Aerts JG, van der Graaf Y, Ardizzoni A, Smit EF.

Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small cell lung cancer: treating the right patients based on individualized treatment effect prediction.

Ann Oncol. 2016 Apr 6. pii: mdw154.

Saber A, van der Wekken AJ, Kok K, Terpstra MM, Bosman LJ, Mastik MF, Timens W, Schuurung E, Hiltermann TJ, Groen HJ, van den Berg A

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing. .

PLoS One. 2016 Apr 5;11(4):e0153065. doi: 10.1371/journal.pone.0153065. eCollection 2016.

Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, Cho BC, Socinski MA, Pandite L, Nase C, Ma B, D'Amelio A Jr, Mookerjee B, Curtis CM Jr, Johnson BE. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

Lancet Oncol. 2016 Apr 11. pii: S1470-2045(16)00077-2. doi: 10.1016/S1470-2045(16)00077-2

Kerner GS, Bollineni VR, Hiltermann TJ, Sijtsema NM, Fischer A, Bongaerts AH, Pruim J, Groen HJ.

An exploratory study of volumetric analysis for assessing tumor response with (18)F-FAZA PET/CT in patients with advanced non-small-cell lung cancer (NSCLC).EJNMMI Res. 2016 Dec;6(1):33. doi: 10.1186/s13550-016-0187-6. Epub 2016 Apr 18.

Heerink WJ, de Bock GH, de Jonge GJ, Groen HJ, Vliegenthart R, Oudkerk M.

Complication rates of CT-guided transthoracic lung biopsy: meta-analysis.Eur Radiol. 2016 Apr 23.

Kerner GS, Koole MJ, Bongaerts AH, Pruim J, Groen HJ; CTMM Air Force Consortium.

Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition.PLoS One. 2016 May 3;11(5):e0149955. doi: 10.1371/journal.pone.0149955. eCollection 2016.

Walter JE, Heuvelmans MA, de Jong PA, Vliegenthart R, van Ooijen PM, Peters RB, Ten Haaf K, Yousaf-Khan U, van der Aalst CM, de Bock GH, Mali W, Groen HJ, de Koning HJ, Oudkerk M.

Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial.

Lancet Oncol. 2016 Jun 6. pii: S1470-2045(16)30069-9. doi: 10.1016/S1470-2045(16)30069-9.

Pore M, Meijer C, de Bock GH, Boersma-van Ek W, Terstappen LW, Groen HJ, Timens W, Kruyt FA, Hiltermann TJ.

Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer.Clin Lung Cancer. 2016 Jun 8. pii: S1525-7304(16)30131-0. doi: 10.1016/j.clc.2016.05.015.

Clausen MJ, Melchers LJ, Mastik MF, Slagter-Menkema L, Groen HJ, van der Laan BF, van Criekinge W, de Meyer T, Denil S, van der Vegt B, Wisman GB, Roodenburg JL, Schuurung E.AB25 expression is epigenetically downregulated in oral and oropharyngeal squamous cell carcinoma with lymph node metastasis.Epigenetics. 2016 Jul 5:0.

Crino L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, Mok T, Spigel D, Felip E, Nishio M, Scagliotti G, Branle F, Emeremni C, Quadrigli M, Zhang J, Shaw AT.

J Clin Oncol. 2016 Jul 18. pii: JCO655936.

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

Hubers AJ, Heideman DA, Duin S, Witte BI, de Koning HJ, Groen HJ, Prinsen CF, Bolijn AS, Wouters M, van der Meer SE, Steenbergen RD, Snijders PJ, Uytterlinde A, Berkhof H, Smit EF, Thunnissen E.

DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2 years.

J Clin Pathol. 2016 Aug 5. pii: jclinpath-2016-203734. doi: 10.1136/jclinpath-2016-203734.

de Jong EE, van Elmpt W, Leijenaar RT, Hoekstra OS, Groen HJ, Smit EF, Boellaard R, van der Noort V, Troost EG, Lambin P, Dingemans AC

[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. Eur J Nucl Med Mol Imaging. 2016 Sep 6.

Louie AV, Chen H, Van Werkhoven E, Smit E, Palma DA, Paul MA, Warner A, Widder J, Groen HJ, van Den Borne B, De Jaeger K, Rodrigues G, Slotman BJ, Senan S.

Quality of Life Following Stereotactic Ablative Radiation Therapy Versus Surgery for Early-Stage Lung Cancer: Results From the ROSEL Randomized Controlled Trial and a Systematic Review. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):S10-S11. doi: 10.1016/j.ijrobp.2016.06.040. No abstract available.

Pore M, Meijer C, de Bock GH, Boersma-van Ek W, Terstappen LW, Groen HJ, Timens W, Kruijt FA, Hiltermann TJ.

Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer. Clin Lung Cancer. 2016 Nov;17(6):535-542. doi: 10.1016/j.clcc.2016.05.015.

Lind JS, Dingemans AC, Groen HJ, Smit EF.

A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2009 May 20;27(15_suppl):8018.

Ragin C, Liu JC, Jones G, Shoyele O, Sowunmi B, Kennett R, Groen HJ, Gibbs D, Blackman E, Esan M, Brandwein MS, Devarajan K, Bussu F, Chernock R, Chien CY, Cohen MA, Samir EM, Mikio S, D'Souza G, Funchain P, Eng C, Gollin SM, Hong A, Jung YS, Kruger M, Lewis J Jr, Morbini P, Landolfo S, Ritta M, Straetmans J, Szarka K, Tachezy R, Worden FP, Nelson D, Gatherer S, Taioli E.

Prevalence of HPV Infection in Racial-Ethnic Subgroups of Head and Neck Cancer Patients. Carcinogenesis. 2016 Dec 26. pii: bgw203. doi: 10.1093/carcin/bgw203.

van Kruijsdijk RC, Visseren FL, Dingemans AC, Groen HJ, Aerts JG, der Graaf YV, Smit EF.

Prediction of treatment effects for individual cancer patients using data from randomized clinical trials. Ann Oncol. 2014 Sep 1;25(suppl_4):iv423. doi: 10.1093/annonc/mdl348.21

Dingemans AC, Groen HJ, Herder G, Smit EF, Burgers S, Stigt J, De Goeije P, Dalesio O, Biesma B, van der Noort V, Aerts JG. Randomized phase ii study of paclitaxel-carboplatin-bevacizumab (pcb) with or without nitroglycerin patches (ntg) in patients (pts) with stage iv non-squamous-non-small cell lung cancer (ns-nscl)(nvalt 12), impact of circulating vascular endothelial growth factor (vegf) levels. Ann Oncol. 2014 Sep 1;25(suppl_4):iv440. doi: 10.1093/annonc/mdl349.32

Hiltermann TJ, Pore MM, Meijer J, Timens W, De Bock GH, Groen HJ, Kruijt FA.

Overall survival in small cell lung cancer detected with epithelial, mesenchymal and stem cell biomarkers. Ann Oncol. 2014 Sep 1;25(suppl_4):iv512. doi: 10.1093/annonc/mdl355.6.

Hobbs BD, de Jong K, Lamontagne M, Bosse Y, Shrine N, Artigas MS, Wain LV, Hall IP, Jackson VE, Wyss AB, London SJ, North KE, Franceschini N, Strachan DP, Beaty TH, Hokanson JE, Crapo JD, Castaldi PJ, Chase RP, Bartz TM, Heckbert SR, Psaty BM, Gharib SA, Zanen P, Lammers JW, Oudkerk M, Groen HJ, Locantore N, Tal-Singer R, Rennard SI, Vestbo J, Timens W, Pare PD, Latourelle JC, Dupuis J, O'Connor GT, Wilk JB, Kim WJ, Lee MK, Oh YM, Vonk JM, de Koning HJ, Leng S, Belinsky SA, Tesfaigzi Y, Manichaikul A, Wang XQ, Rich SS, Barr RG, Sparrow D, Litonjua AA, Bakke P, Gulsvik A, Lahousse L, Brusselle GG, Stricker BH, Uitterlinden AG, Ampleford EJ, Bleeker ER, Woodruff PG, Meyers DA, Qiao D, Lomas DA, Yim JJ, Kim DK, Hawrylykiewicz I, Sliwinski P, Hardin M, Fingerlin TE, Schwartz DA, Postma DS, MacNee W, Tobin MD, Silverman EK, Boezen HM, Cho MH; COPDGene Investigators.; ECLIPSE Investigators.; LifeLines Investigators.; SPIROMICS Research Group.; International COPD Genetics Network Investigators.; UK BiLEVE Investigators.; International COPD Genetics Consortium.

Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. Nat Genet. 2017 Feb 6. doi: 10.1038/ng.3752.

van der Wekken A, Pelgrim R, 't Hart N, Werner N, Mastik M, Hendriks L, van der Heijden EH, Looijen-Salamon M, de Langen AJ, Staal-van den Brekel J, Riemersma S, van den Borne BE, Speel EM, Dingemans AC, Hiltermann TJ, van den Berg A, Timens W, Schuurung E, Groen HJ. Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non-small cell lung cancer. *Clin Cancer Res*. 2017 Feb 9. pii: clincanres.1631.2016. doi: 10.1158/1078-0432.CCR-16-1631.

van der Linden N, Bongers ML, Coupe VM, Smit EF, Groen HJ, Welling A, Schramel FM, Uyl-de Groot CA. Treatment Patterns and Differences in Survival of Non-Small Cell Lung Cancer Patients Between Academic and Non-Academic Hospitals in the Netherlands.

Clin Lung Cancer. 2015 Nov 30. pii: S1525-7304(15)00275-2. doi: 10.1016/j.clc.2015.11.011.

Ferronika P, van den Bos H, Taudt A, Spierings DCJ, Saber A, Hiltermann TJN, Kok K, Porubsky D, van der Wekken AJ, Timens W, Foiyer F, Colome-Tatche M, Groen HJM, Lansdorp PM, van den Berg A.

Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small cell lung cancer patient. *Ann Oncol*. 2017 Apr 11. doi: 10.1093/annonc/mdx182.

Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodriguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. *J Clin Oncol*. 2017 May 5;JCO2016715904. doi: 10.1200/JCO.2016.71.5904

Soo RA, Stone EC, Cummings KM, Jett JR, Field JK, Groen HJ, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JC, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR.

Scientific Advances in Thoracic Oncology 2016. *J Thorac Oncol*. 2017 May 27. pii: S1556-0864(17)30427-6. doi: 10.1016/j.jtho.2017.05.019.

Lodeweges JE, Klinkenberg TJ, Ubbels JF, Groen HJM, Langendijk JA, Widder J.

Brief report: Long-term Outcome of Surgery or Stereotactic Radiotherapy for Lung Oligometastases. *J Thorac Oncol*. 2017 May 30. pii: S1556-0864(17)30423-9. doi: 10.1016/j.jtho.2017.05.015.

Derks JL, van Suylen RJ, Thunnissen E, den Bakker MA, Groen HJ, Smit EF, Damhuis RA, van den Broek EC, Speel EM, Dingemans AC; PALGA group.

Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? *Eur Respir J*. 2017 Jun 1;49(6). pii: 1601838. doi: 10.1183/13993003.01838-2016. Print 2017 Jun.

Hijmering-Kappelle LBM, van der Wekken AJ, Hiltermann TJN, Groen HJM.

New biopsy at lung cancer progression: rational treatment of resistant lung cancer. *Ned Tijdschr Geneeskd*. 2017;161(0):D1229. Dutch.

van Kooten MJ, van den Berg G, Glaudemans AWJM, Hiltermann TJN, Groen HJM, Rutgers A, Links TP.

Transient thyrotoxicosis during nivolumab treatment.

Neth J Med. 2017 Jun;75(5):204-207.

Heuvelmans MA, Vliegenthart R, de Koning HJ, Groen HJM, van Putten MJAM, Yousaf-Khan U, Weenink C, Nackaerts K, de Jong PA, Oudkerk M.

Quantification of growth patterns of screen-detected lung cancers: The NELSON study. *Lung Cancer*. 2017 Jun;108:48-54. doi: 10.1016/j.lungcan.2017.02.021. Epub 2017 Mar 1.

1215PPrediction of treatment effects for individual cancer patients using data from randomized clinical trials. van Kruijsdijk RC, Visseren FL, Dingemans AC, Groen HJ, Aerts JG, der Graaf YV, Smit EF.

Ann Oncol. 2014 Sep 1;25(suppl_4):iv423. doi: 10.1093/annonc/mdu348.21.

1253PA Randomized phase ii study of paclitaxel-carboplatin-bevacizumab (pcb) with or without nitroglycerin patches (ntg) in patients (pts) with stage iv non-squamous-non-small cell lung cancer (ns-nsclc)(nvalt 12), impact of circulating vascular endothelial growth factor (vegf) levels. Dingemans AC, Groen HJ, Herder G, Smit EF, Burgers S, Stigt J, De Goeije P, Dalesio O, Biesma B, van der Noort V, Aerts JG.

1468POverall survival in small cell lung cancer detected with epithelial, mesenchymal and stem cell biomarkers. Hiltermann TJ, Pore MM, Meijer J, Timens W, De Bock GH, Groen HJ, Kruijt FA.

Ann Oncol. 2014 Sep 1;25(suppl_4):iv512. doi: 10.1093/annonc/mdu355.6.

de Jong EEC, van Elmpt W, Hoekstra OS, Groen HJM, Smit EF, Boellaard R, Lambin P, Dingemans AC

Quality assessment of positron emission tomography scans: recommendations for future multicentre trials. Acta Oncol. 2017 Aug 22;1-6. doi: 10.1080/0284186X.2017.1346824.

van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, Thunnissen E, Heideman DAM, Timens W, Schuurin E, Kok K, Smit EF, van den Berg A, Groen HJM.

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression. PLoS One. 2017 Aug 30;12(8):e0182885. doi: 10.1371/journal.pone.0182885. eCollection 2017.

Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland A, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE.

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Sep 8. pii: S1470-2045(17)30679-4. doi: 10.1016/S1470-2045(17)30679-4.

Soria JC, Adjei AA, Bahleda R, Besse B, Ferte C, Planchard D, Zhou J, Ware J, Morrissey K, Shankar G, Lin W, Schutzman JL, Dy GK, Groen HJM.

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer. Eur J Cancer. 2017 Oct 6;86:186-196. doi: 10.1016/j.ejca.2017.08.027.

van der Velden DL, van Herpen CML, van Laarhoven HWM, Smit EF, Groen HJM, Willems SM, Nederlof PM, Langenberg MHG, Cuppen E, Sleijfer S, Steeghs N, Voest EE.

Molecular Tumor Boards: Current Practice and Future Needs. Ann Oncol. 2017 Sep 27. doi: 10.1093/annonc/mdx528.

Derks J, Leblay N, Thunnissen E, van Suylen RJ, den Bakker M, Groen HJ, Smit EF, Damhuis R, van den Broek EC, Chabrier A, Foll M, McKay JD, Fernandez-Cuesta L, Speel EM, Dingemans AC.

Molecular subtypes of pulmonary large cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2017 Oct 24. pii: clincanres.1921.2017. doi: 10.1158/1078-0432.CCR-17-1921.

Horn L, Gettinger S, Camidge DR, Smit EF, Janjigian YY, Miller VA, Pao W, Freiwald M, Fan J, Wang B, Chand VK, Groen HJM

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung Cancer. 2017 Nov;113:51-58. doi: 10.1016/j.lungcan.2017.08.014. Epub 2017 Aug 31.

Heuvelmans MA, Walter JE, Peters RB, Bock GH, Yousaf-Khan U, Aalst CMV, Groen HJM, Nackaerts K, Ooijen PMV, Koning HJ, Oudkerk M, Vliegenthart R.

Relationship between nodule count and lung cancer probability in baseline CT lung cancer screening: The NELSON study. Lung Cancer. 2017 Nov;113:45-50. doi: 10.1016/j.lungcan.2017.08.023. Epub 2017 Sep 1.

Brinkhof S, Groen HJM, Siesling SS, IJzerman MJ.

Resource utilization in lung cancer diagnostic procedures: Current use and budget consequences. PLoS One. 2017 Dec 7;12(12):e0189251. doi: 10.1371/journal.pone.0189251. eCollection 2017.

Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim SW, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim DW, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB.

Brief Report: Phase 2 Study of the HSP-90 inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 Dec 13. pii: S1556-0864(17)33083-6. doi: 10.1016/j.jtho.2017.11.131

W. J, van der Wekken AJ, Saber A, Terpstra MM, Schuurin E, Timens W, Hiltermann TJN, Groen HJM, van den Berg A, Kok K.

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers. Cancers (Basel). 2018 Jan 4;10(1). pii: E10. doi: 10.3390/cancers10010010.

Li J, Wang Z, Groen HJM, Zhao J, Wang P, Zhang C, Yang K, Guo Y, Ma J.
Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs. *Lung Cancer*. 2018 Mar 1. pii: S0169-5002(18)30273-3. doi: 10.1016/j.lungcan.2018.02.016.

Walter JE, Heuvelmans MA, Bock GH, Yousaf-Khan U, Groen HJM, Aalst CMV, Nackaerts K, Ooijen PMAV, Koning HJ, Vliegthart R, Oudkerk M.
Characteristics of new solid nodules detected in incidence screening rounds of low-dose CT lung cancer screening: the NELSON study. *Thorax*. 2018 Apr 16. pii: thoraxjnl-2017-211376. doi: 10.1136/thoraxjnl-2017-211376.

De Ruyscher D, Dingemans AC, Praag J, Belderbos J, Tissing-Tan C, Herder J, Haitjema T, Ubbels F, Lagerwaard F, El Sharouni SY, Stigt JA, Smit E, van Tinteren H, van der Noort V, Groen HJM.
Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study. *J Clin Oncol*. 2018 May 22;JCO2017775817. doi: 10.1200/JCO.2017.77.5817.

Meedendorp AD, Ter Elst A, 't Hart NA, Groen HJM, Schuurin E, van der Wekken AJ.
Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification. *Front Oncol*. 2018 May 22;8:176. doi: 10.3389/fonc.2018.00176. eCollection 2018.

van der Wekken AJ, Kok K, Groen HJM.
Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer? *J Thorac Dis*. 2018 Jul;10(Suppl 18):S2130-S2132. doi: 10.21037/jtd.2018.06.45.

Yang K, Li J, Zhao J, Ren P, Wang Z, Wei B, Dong B, Sun R, Wang X, Groen HJM, Ma J, Guo Y
Developing ultra-sensitive library aliquot-based droplet digital PCR for detecting T790M in plasma circulating tumor DNA of non-small-cell lung cancer patients. *Anal Chem*. 2018 Aug 29. doi: 10.1021/acs.analchem.8b01776.

De Ruyscher DK, Groen HJ.
Prophylactic cranial irradiation (PCI) in locally advanced non-small cell lung cancer: time for hope? *Oncotarget*. 2018 Aug 17;9(64):32274-32275. doi: 10.18632/oncotarget.25866. eCollection 2018 Aug 17..

Wouters MPAM, Wolffenbuttel BHR, Links TP, Groen HJM, Wouters RSME
An enlarged thymus associated with Graves' disease. *Ned Tijdschr Geneeskd*. 2018 Jul 20;162. pii: D2905. Dutch.

Heerink WJ, Dorrius MD, Groen HJM, Van Ooijen PMA, Vliegthart R, Oudkerk M.
Respiratory level tracking with visual biofeedback for consistent breath-hold level with potential application in image-guided interventions. *Eur Radiol Exp*. 2018 Sep 5;2:22. doi: 10.1186/s41747-018-0052-7. eCollection 2018 Dec.

de Wit S, Zeune LL, Hiltermann TJN, Groen HJM, Dalum GV, Terstappen LWMM.
Classification of Cells in CTC-Enriched Samples by Advanced Image Analysis. *Cancers (Basel)*. 2018 Oct 10;10(10). pii: E377. doi: 10.3390/cancers10100377.

de Boer HR, Pool M, Joosten E, Everts M, Samplonius DF, Helfrich W, Groen HJM, van Cooten S, Fusetti F, Fehrmann RSN, de Vries EGE, van Vugt MATM.
Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition. *Oncogene*. 2018 Oct 10. doi: 10.1038/s41388-018-0522-7.

Atrafi F, Groen HJ, Byers LA, Garralda E, Lolkema M, Sangha R, Viteri S, Chae YK, Camidge DR, Gabrail N, Hu B, Tian T, Nuthalapati S, Hoening E, He L, Komarnitsky P, Calles A.
A Phase 1 Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. *Clin Cancer Res*. 2018 Oct 16. pii: clincanres.2014.2018. doi: 10.1158/1078-0432.CCR-18-2014.

De Ruyscher DK, Groen HJ.
Reply to A. Addeo et al, H. Zeng et al, and C.G. Rusthoven. *J Clin Oncol*. 2018 Oct 22;JCO1800863. doi: 10.1200/JCO.18.00863.

Walter JE, Heuvelmans MA, de Bock GH, Yousaf-Khan U, Groen HJM, van der Aalst CM, Nackaerts K, van Ooijen PMA, de Koning HJ, Vliegthart R, Oudkerk M.
Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON study. *Lung Cancer*. 2018 Nov;125:103-108. doi: 10.1016/j.lungcan.2018.05.007. Epub 2018 May 14.

Niemantsverdriet M, Schuurung E, Elst AT, van der Wekken AJ, van Kempen LC, van den Berg A, Groen HJM.

KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC. *J Thorac Oncol*. 2018 Dec;13(12):e249-e251. doi: 10.1016/j.jtho.2018.07.103.

Broekhuizen H, Groothuis-Oudshoorn CGM, Vliegenthart R, Groen HJM, IJzerman MJ.

Assessing Lung Cancer Screening Programs under Uncertainty in a Heterogeneous Population. *Value Health*. 2018 Nov;21(11):1269-1277. doi: 10.1016/j.jval.2018.01.021.

Cramer-van der Welle CM, Peters BJM, Schramel FMNH, Klungel OH, Groen HJM, van de Garde EMW; Santeon NSCLC Study Group.

Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic NSCLC. *Eur Respir J*. 2018 Nov 28. pii: 1801100. doi: 10.1183/13993003.01100-2018.

Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schroder CP, Hiltermann TJN, van der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA, Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers AH, Fine BM, de Vries EGE.

⁸⁹Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. *Nat Med*. 2018 Nov 26. doi: 10.1038/s41591-018-0255-8.

Klinkenberg TJ, Bouma W, Van De Wauwer C, Wolf RFE, Mariani MA, Groen HJM.

Surgical experience and patient-related restrictions predict the adequacy of cervical mediastinoscopy in non-small cell lung carcinoma lymph node staging. *J Cardiothorac Surg*. 2018 Dec 29;13(1):134. doi: 10.1186/s13019-018-0821-7.

Walter JE, Heuvelmans MA, Ten Haaf K, Vliegenthart R, van der Aalst CM, Yousaf-Khan U, van Ooijen PMA, Nackaerts K, Groen HJM, De Bock GH, de Koning HJ, Oudkerk M.

Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study. *Thorax*. 2018 Dec 27. pii: thoraxjnl-2018-212152. doi: 10.1136/thoraxjnl-2018-212152.

de Goeje PL, Poncin M, Bezemer K, Kaijen-Lambers MEH, Groen HJ, Smit EF, Dingemans AC, Kunert A, Hendriks RW, Aerts JG. Induction of peripheral effector CD8 T cell proliferation by combination of paclitaxel, carboplatin and bevacizumab in non-small cell lung cancer patients. *Clin Cancer Res*. 2019 Jan 14. pii: clincanres.2243.2018. doi: 10.1158/1078-0432.CCR-18-2243.

1. 2019

2. Tamminga, M., & Groen, H. J. M. (2019). Circulating tumor cells are prognostic in SCLC, but still lack clinical application. *Annals of Oncology*, 30(7), 1031-1033.

<https://doi.org/10.1093/annonc/mdz162>

3. Hiltermann, T. J. N., Hijmering-Kappelle, L. B. M., Azpurua, M. L. A., van der Wekken, A. J., Hiddinga, B. L., Timens, W., ... Schuurung, E. (2019). ctDNA a promising predictive marker for treatment with PD-1 inhibitors in KRAS mutated NSCLC after platinum based chemotherapy. *Cancer Research*, 79(13). <https://doi.org/10.1158/1538-7445.AM2019-399>

4. Santos, J. F. V. M. R., Hiddinga, B. I., van Kempen, L. C., ter Elst, A., Hijmering, L. B., Hiltermann, T. J., ... van der Wekken, A. J. (2019). Modeling of drug-protein interactions to support clinical decision making for therapy-resistant EGFR or ALK-positive non-small cell lung carcinoma. *Cancer Research*, 79(13). <https://doi.org/10.1158/1538-7445.AM2019-1398>

5. IMI CANC-ID Consortium (2019). Standardization and clinical implementation of liquid biopsy assays - IMI's CANCER-ID. *Cancer Research*, 79(13). <https://doi.org/10.1158/1538-7445.SABCS18-3190>

6. Degens, J. H. R. J., Sanders, K. J. C., de Jong, E. E. C., Groen, H. J. M., Smit, E. F., Aerts, J. G., ... Dingemans, A-M. C. (2019). The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer. *Lung Cancer*, 133, 130-135. <https://doi.org/10.1016/j.lungcan.2019.05.021>

7. Nanou, A., Zeune, L. L., de Wit, S., Miller, C. M., Punt, C. J., Groen, H. J., ... Terstappen, L. W. (2019). Tumor-derived extracellular vesicles in blood of metastatic breast, colorectal, prostate, and non-small cell lung cancer patients associate with worse survival. *Cancer Research*, 79(13). <https://doi.org/10.1158/1538-7445.AM2019-4464>

8. Witlox, W. J. A., Ramaekers, B. L. T., Groen, H. J. M., Dingemans, A. M., Praag, J., Belderbos, J., ... De Ruyscher, D. K. M. (2019). Factors determining the effect of prophylactic cranial irradiation (PCI) in patients with stage-III nonsmall cell lung cancer: exploratory subgroup analyses of the NVALT-11/DLCRG-02 phase-III study. *ACTA ONCOLOGICA*. <https://doi.org/10.1002/ajco.22841>

9. de Wit, S., Rossi, E., Weber, S., Tamminga, M., Manicone, M., Swennenhuis, J. F., ... Groen, H. J. M. (2019). Single tube liquid biopsy for advanced non-small cell lung cancer. *International Journal of Cancer*, 144(12), 3127-3137. <https://doi.org/10.1002/ijc.32056>

10. Wei, B., Li, J., Ren, P., Chang, Y., Zhao, C., Xia, Q., ... Guo, Y. (2019). An optimized workflow for a fast molecular diagnosis of non-small cell lung cancer. *Journal of Clinical Oncology*, 37(15). https://doi.org/10.1200/JCO.2019.37.15_suppl.e13139
11. Wolf, J., Seto, T., Han, J.-Y., Reguart, N., Garon, E. B., Groen, H. J. M., ... Heist, R. S. (2019). Capmatinib (INC280) in MET Delta ex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. *Journal of Clinical Oncology*, 37(15).
12. Ramdani, H. O. E. K., Falk, M., Schatz, S., Tiemann, M., Heukamp, L., Schuurin, E., ... Griesinger, F. (2019). Evaluation of combined biomarkers for tumor response to immunotherapy (I/O) in patients with advanced non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology*, 37(15). https://doi.org/10.1200/JCO.2019.37.15_suppl.e14269
13. Li, J., Zhang, C., Zhao, J., Wang, Z., Wei, B., Sun, R., ... Guo, Y. (2019). The targetable mutation landscape of Chinese patients with non-small cell lung cancer. *Journal of Clinical Oncology*, 37(15). https://doi.org/10.1200/JCO.2019.37.15_suppl.e13018
14. Groen, H. J. M., & Hiltermann, T. J. N. (2019). Air Pollution and Adenocarcinoma in Never-Smokers. *Journal of Thoracic Oncology*, 14(5), 761-763. <https://doi.org/10.1016/j.jtho.2019.02.007>
15. Heuvelmans, M. A., Vonder, M., Rook, M., Groen, H. J. M., De Bock, G. H., Xie, X., ... Oudkerk, M. (2019). Screening for Early Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease (the Big-3) Using Low-dose Chest Computed Tomography: Current Evidence and Technical Considerations. *Journal of thoracic imaging*, 34(3), 160-169. <https://doi.org/10.1097/RTI.0000000000000379>
16. Pantel, K., Terstappen, L. W. M. M., manaresi, N., Groen, H. J. M., Tamminga, M., Schuurin, E., ... Schlange, T. (2019). Standardization and clinical implementation of liquid biopsy assays - IMI's CANCER-ID. Poster session presented at AACR annual meeting 2019, Atlanta, United States.
17. Lindsay, C. R., Blackhall, F. H., Carmel, A., Gazzaniga, P., Groen, H. J. M., Krebs, M. G., ... Michiels, S. (2019). EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer. *Annals of Oncology*, 30 (Suppl 2), ii7. <https://doi.org/10.1093/annonc/mdz073>
18. Dumoulin, D., de Goeje, P., Poncin, M., Bezemer, K., Groen, H. J. M., Smit, E. F., ... Aerts, J. G. (2019). Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors. *Annals of Oncology*, 30 (Suppl 2), ii7. <https://doi.org/10.1093/annonc/mdz073.001>
19. PALGA Grp (2019). Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). *Lung Cancer*, 130, 179-186. <https://doi.org/10.1016/j.lungcan.2019.02.022>
20. Witlox, W. J. A., Ramaekers, B., Groen, H. J. M., Dingemans, A-M. C., Praag, J., Belderbos, J., ... De Ruyscher, D. (2019). The effect of prophylactic cranial irradiation (PCI) for young stage III NSCLC patients: Subgroup analyses of the NVALT-11/DLCRG-02 study. *Annals of Oncology*, 30(Suppl 2), 33-34. <https://doi.org/10.1093/annonc/mdz067.003>
21. Walter, J. E., Heuvelmans, M. A., ten Haaf, K., Vliegenthart, R., van der Aalst, C. M., Yousaf-Khan, U., ... Oudkerk, M. (2019). Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study. *Thorax*, 74(3), 247-253. <https://doi.org/10.1136/thorax-2018-212152>
22. de Boer, H. R., Pool, M., Joosten, E., Everts, M., Samplonius, D. F., Helfrich, W., ... van Vugt, M. A. T. M. (2019). Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition. *ONCOGENE*, 38(9), 1477-1488. <https://doi.org/10.1038/s41388-018-0522-7>
23. Du, Y., Zhao, Y., Sidorenkov, G., de Bock, G. H., Cui, X., Huang, Y., ... Ye, Z. (2019). Methods of computed tomography screening and management of lung cancer in Tianjin: Design of a population-based cohort study. *Cancer biology & medicine*, 16(1), 181-188. <https://doi.org/10.1007/s12095-018-0237-7>
24. Atrafi, F., Groen, H. J. M., Byers, L. A., Garralda, E., Lolkema, M. P., Sangha, R. S., ... Calles, A. (2019). A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. *Clinical Cancer Research*, 25(2), 496-505. <https://doi.org/10.1158/1078-0432.CCR-18-2014>
25. PALGA Grp (2019). DLL3 in Large Cell Neuroendocrine Carcinoma (LCNEC) Associated with Molecular Subtypes. *Neuroendocrinology*, 108, 122-122.
26. Ramdani, H., Falk, M., Schatz, S., Tiemann, M., Heukamp, L. C., Schuurin, E., ... Griesinger, F. (2019). Evaluation of combined biomarkers for tumor response to immunotherapy (I/O) in patients with advanced non-small cell lung cancer (NSCLC). *Oncology Research and Treatment*, 42, 77-77.

27. Holleman, M. S., van Tinteren, H., Groen, H. J. M., Al, M. J., & Uyl-de Groot, C. A. (2019). First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. *Oncotargets and therapy*, 12, 1413-1421. <https://doi.org/10.2147/OTT.S189438>
28. PALGA Grp (2019). Prevalence and Prognostic Value of PD-L1 Expression in Molecular Subtypes of Metastatic Large Cell Neuroendocrine Carcinoma (LCNEC). *Neuroendocrinology*, 108, 171-171.
29. 2018
30. Klinkenberg, T. J., Bouma, W., Van De Wauwer, C., Wolf, R. F. E., Mariani, M. A., & Groen, H. J. M. (2018). Surgical experience and patient-related restrictions predict the adequacy of cervical mediastinoscopy in non-small cell lung carcinoma lymph node staging. *Journal of cardiothoracic surgery*, 13(1), 134. [134]. <https://doi.org/10.1093/cts/13.1.134>
31. De Ruyscher, D. K., & Groen, H. J. (2018). Reply to A. Addeo et al, H. Zeng et al, and C.G. Rusthoven. *Journal of Clinical Oncology*, 36(34), 3434-+. <https://doi.org/10.1200/JCO.2018.00863>
32. Santeon NSCLC Study Grp, Cramer-van der Welle, C. M., Peters, B. J. M., Schramel, F. M. N. H., Klungel, O. H., Groen, H. J. M., ... Termeer, A. (2018). Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer. *European Respiratory Journal*, 52(6), [1801100]. <https://doi.org/10.1183/13993003.01100-2018>
33. Niemantsverdriet, M., Schuurin, E., Elst, A. T., van der Wekken, A. J., van Kempen, L. C., van den Berg, A., & Groen, H. J. M. (2018). KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC. *Journal of Thoracic Oncology*, 13(12), E249-E251. <https://doi.org/10.1016/j.jtho.2018.07.103>
34. Heerink, W. J., Dorrius, M. D., Groen, H. J. M., Van Ooijen, P. M. A., Vliegthart, R., & Oudkerk, M. (2018). Respiratory level tracking with visual biofeedback for consistent breath-hold level with potential application in image-guided interventions. *European Radiology Experimental*, 2(22). <https://doi.org/10.1007/s41747-018-0052-7>
35. Bensch, F., van der Veen, E. L., Lub-de Hooge, M. N., Jorritsma-Smit, A., Boellaard, R., Kok, I. C., ... de Vries, E. G. E. (2018). Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. *Nature Medicine*, 24(12), 1852-1858. <https://doi.org/10.1038/s41591-018-0255-8>
36. Broekhuizen, H., Groothuis-Oudshoorn, C. G. M., Vliegthart, R., Groen, H. J. M., & IJzerman, M. J. (2018). Assessing Lung Cancer Screening Programs under Uncertainty in a Heterogeneous Population. *Value in Health*, 21(11), 1269-1277. <https://doi.org/10.1016/j.jval.2018.01.021>
37. Walter, J. E., Heuvelmans, M. A., de Bock, G. H., Yousaf-Khan, U., Groen, H. J. M., van der Aalst, C. M., ... Oudkerk, M. (2018). Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON study. *Lung Cancer*, 125, 103-108. <https://doi.org/10.1016/j.lungcan.2018.05.007>
38. Yang, K., Li, J., Zhao, J., Ren, P., Wang, Z., Wei, B., ... Guo, Y. (2018). Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients. *Analytical Chemistry*, 90(19), 11203-11209. <https://doi.org/10.1021/acs.analchem.8b01776>
39. Paz-Ares, L., Urban, L., Audigier-Valette, C., Grossi, F., Jao, K., Aucoin, J., ... Ready, N. (2018). CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC. *Journal of Thoracic Oncology*, 13(10), S493-S493. <https://doi.org/10.1016/j.jtho.2018.08.635>
40. de Wit, S., Zeune, L. L., Hiltermann, T. J. N., Groen, H. J. M., van Dalum, G., & Terstappen, L. W. M. M. (2018). Classification of Cells in CTC-Enriched Samples by Advanced Image Analysis. *Cancers*, 10(10), [377]. <https://doi.org/10.3390/cancers10100377>
41. P PALGA-Grp (2018). Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). *Annals of Oncology*, 29, 643.
42. Wolf, J., Seto, T., Han, J.-Y., Reguart, N., Garon, E. B., Groen, H. J. M., ... Heist, R. S. (2018). Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with MET Delta ex14 mutated advanced non-small cell lung cancer (NSCLC). *Annals of Oncology*, 29(Suppl.8).
43. Walter, J. E., Heuvelmans, M. A., Yousaf-Khan, U., Dorrius, M. D., Thunnissen, E., Schermann, A., ... Oudkerk, M. (2018). New Subsolid Pulmonary Nodules in Lung Cancer Screening: The NELSON Trial. *Journal of Thoracic Oncology*, 13(9), 1410-1414. <https://doi.org/10.1016/j.jtho.2018.05.006>
44. De Ruyscher, D. K., & Groen, H. J. (2018). Prophylactic cranial irradiation (PCI) in locally

advanced non-small cell lung cancer: time for hope? *Oncotarget*, 9(64), 32274-32275.
<https://doi.org/10.1080/15388759.2018.1538875>

45. De Ruyscher, D., Dingemans, A-M. C., Praag, J., Belderbos, J., Tissing-Tan, C., Herder, J., ... Groen, H. J. M. (2018). Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study. *Journal of Clinical Oncology*, 36(23), 2366-2377. <https://doi.org/10.1200/JCO.2017.77.5817>
46. Walter, J. E., Heuvelmans, M. A., de Bock, G. H., Yousaf-Khan, U., Groen, H. J. M., van der Aalst, C. M., ... Oudkerk, M. (2018). Characteristics of new solid nodules detected in incidence screening rounds of low-dose CT lung cancer screening: The NELSON study. *Thorax*, 73(8), 741-747. <https://doi.org/10.1136/thorax-2017-211376>
47. Wouters, M. P. A. M., Wolffenbuttel, B. H. R., Links, T. P., Groen, H. J. M., & Wouters, R. S. M. E. (2018). Een vergrote thymus bij ziekte van Graves. *Nederlands Tijdschrift voor Geneeskunde*, 162(34), [D2905].
48. Tamminga, M., de Wit, S., Swennenhuis, J. F., Hiltermann, T. J. N., Schuurings, E. M., Terstappen, L. W. M., & Groen, H. J. (2018). Circulating tumor cells and tumor-derived extracellular vesicles as a possible marker for tumor response and survival in patients with non-small cell lung cancer treated with immunotherapy. *Cancer Research*, 78(13). <https://doi.org/10.1158/1538-7445.AM2018-3606>
49. Andree, K. C., Tamminga, M., Mentink, A., Hilterman, T. J., Groen, H. J., & Terstappen, L. W. (2018). Circulating tumor cells in the peripheral blood and leukapheresis product of non-small cell lung cancer patients. *Cancer Research*, 78(13). <https://doi.org/10.1158/1538-7445.AM2018-5584>
50. Tamminga, M., de Wit, S., Swennenhuis, J. F., Heitzer, E., Speicher, M., Hiltermann, T. J. N., ... Groen, H. J. (2018). Circulating tumor cells measured in the pulmonary vein and radial artery during surgery of non-small cell lung cancer. *Cancer Research*, 78(13). <https://doi.org/10.1158/1538-7445.AM2018-5594>
51. van der Wekken, A. J., Kok, K., & Groen, H. J. M. (2018). Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer? *Journal of thoracic disease*, 10(Supp 18), S2130-S2132. <https://doi.org/10.21037/jtd.2018.06.45>
52. Meedendorp, A. D., Ter Elst, A., 't Hart, N. A., Groen, H. J. M., Schuurings, E., & van der Wekken, A. J. (2018). Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification. *Frontiers in Oncology*, 8, [176]. <https://doi.org/10.3389/fonc.2018.00176>
1. 2020
2. Wei, J., Rybczynska, A. A., Meng, P., Terpstra, M., Saber, A., Sietzema, J., ... Kok, K. (2020). An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients. *Cancers*, 12(10), [2843]. <https://doi.org/10.3390/cancers12102843>
3. GEOMETRY Mono-1, Wolf, J., Seto, T., Han, J-Y., Reguart, N., Garon, E. B., ... Heist, R. S. (2020). Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, 383(10), 944-957. <https://doi.org/10.1056/NEJMoa2002787>
4. Perakis, S. O., Weber, S., Zhou, Q., Graf, R., Hojas, S., Riedl, J. M., ... Speicher, M. R. (2020). Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer. *ESMO Open*, 5(5), [e000872]. <https://doi.org/10.1093/esmoopen/2020-000872>
5. Meng, P., Koopman, B., Kok, K., Elst, ter, A., Schuurings, E., van Kempen, L., ... van der Wekken, A. J. (2020). Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation. *Lung Cancer*, 146, 358-361. <https://doi.org/10.1016/j.lungcan.2020.05.036>
6. Du, Y., Sidorenkov, G., Heuvelmans, M. A., Groen, H. J. M., Vermeulen, K. M., Greuter, M. J. W., & de Bock, G. H. (2020). Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study. *European Journal of Cancer*, 135, 121-129. <https://doi.org/10.1016/j.ejca.2020.05.004>
7. Tamminga, M., Oomens, L., Hiltermann, T. J. N., Andree, K. C., Tibbe, A., Broekmaat, J., ... Groen, H. J. M. (2020). Microsieves for the detection of circulating tumor cells in leukapheresis product in non-small cell lung cancer patients. *Translational lung cancer research*, 9(4), 1093-1100. <https://doi.org/10.21037/tlcr-19-413>
8. Hurkmans, D. P., Tamminga, M., van Es, B., Peters, T., Karman, W., van Wijck, R. T. A., ... Groen, H. J. M. (2020). Molecular data show conserved DNA locations distinguishing lung cancer subtypes and regulation of immune genes. *Lung Cancer*, 146, 341-349. <https://doi.org/10.1016/j.lungcan.2020.06.008>

9. Du, Y., Sidorenkov, G., Heuvelmans, M. A., Groen, H. J. M., Vermeulen, K. M., Greuter, M. J. W., & de Bock, G. H. (2020). Supplementary data for a model-based health economic evaluation on lung cancer screening with low-dose computed tomography in a high-risk population. *Data in brief*, 31, [105999]. <https://doi.org/10.1016/j.dib.2020.105999>, <https://doi.org/10.1016/j.dib.2020.105999>
10. Cui, X., Heuvelmans, M. A., Fan, S., Han, D., Zheng, S., Du, Y., ... Ye, Z. (2020). A Subsolid Nodules Imaging Reporting System (SSN-IRS) for Classifying 3 Subtypes of Pulmonary Adenocarcinoma. *Clinical lung cancer*, 21(4), 314-+. <https://doi.org/10.1016/j.clcc.2020.01.014>
11. Cui, X., Fan, S., Heuvelmans, M. A., Han, D., Zhao, Y., Groen, H. J. M., ... Ye, Z. (2020). Optimization of CT windowing for diagnosing invasiveness of adenocarcinoma presenting as sub-solid nodules. *European Journal of Radiology*, 128, [108981]. <https://doi.org/10.1016/j.ejrad.2020.108981>
12. Brouns, A. J. W. M., Hendriks, L. E. L., van der Noort, V., van de Borne, B. E. E. M., Schramel, F. M. N. H., Groen, H. J. M., ... Dingemans, A-M. C. (2020). Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial. *Frontiers in Oncology*, 10, [890]. <https://doi.org/10.3389/fonc.2020.00890>
13. Schatz, S., Falk, M., Jori, B., Ramdani, H. O., Schmidt, S., Willing, E-M., ... Heukamp, L. C. (2020). Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer. *Cancers*, 12(6), [1685]. <https://doi.org/10.3390/cancers12061685>
14. Tamminga, M., Hiltermann, T. J. N., Schuurin, E., Timens, W., Fehrmann, R. S. N., & Groen, H. J. M. (2020). Immune microenvironment composition in non-small cell lung cancer and its association with survival. *Clinical & translational immunology*, 9(6), [1142]. <https://doi.org/10.1002/cti2.1142>
15. Tamminga, M., & Groen, H. J. M. (2020). Required Evidence for Clinical Applications of Liquid Biopsy Using Especially CTCs in Lung Cancer. *Applied Sciences*, 10(11), [3704]. <https://doi.org/10.3390/app10113704>
16. Gijtenbeek, R. G. P., Damhuis, R. A. M., Groen, H. J. M., van der Wekken, A. J., & van Geffen, W. H. (2020). Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer. *Clinical lung cancer*. <https://doi.org/10.1016/j.clcc.2020.05.019>
17. Wolf, J., Overbeck, T. R., Han, J-Y., Hochmair, M., de Marinis, F., Ohashi, K., ... Heist, R. S. (2020). Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. *Journal of Clinical Oncology*, 38(15).
18. Groen, H. J. M., Akerley, W. L., Souquet, P. J., Laack, E., Han, J-Y., Smit, E. F., ... Orlov, S. (2020). Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study. *Journal of Clinical Oncology*, 38(15).
19. Santeon SCLC Study Grp, Cramer-van der Welle, C. M., Schramel, F. M. N. H., van Leeuwen, A. S., Groen, H. J. M., & van de Garde, E. M. W. (2020). Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer. *European journal of cancer care*, e13250. [13250]. <https://doi.org/10.1111/ecc.13250>
20. Leest, P. V. D., Boonstra, P. A., Elst, A. T., Kempen, L. C. V., Tibbesma, M., Koopmans, J., ... Schuurin, E. (2020). Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients. *Cancers*, 12(5). <https://doi.org/10.3390/cancers12051222>
21. Koopman, B., van der Wekken, A. J., Elst, ter, A., Hiltermann, J., Vilacha, J. F., Groves, M., ... Kempen, van, L. (2020). Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles. *JCO Precision Oncology*, 4, 393-410. <https://doi.org/10.1200/PO.20.00008>
22. Tamminga, M., Andree, K. C., Hiltermann, T. J. N., Jayat, M., Schuurin, E., van den Bos, H., ... Groen, H. J. M. (2020). Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch(R) and ISET. *Cancers*, 12(4), [896]. <https://doi.org/10.3390/cancers12040896>
23. Du, Y., Cui, X., Sidorenkov, G., Groen, H. J. M., Vliegenthart, R., Heuvelmans, M. A., ... de Bock, G. H. (2020). Lung cancer occurrence attributable to passive smoking among never smokers in China: a systematic review and meta-analysis. *Translational lung cancer research*, 9(2), 204-217. <https://doi.org/10.21037/tlcr.2020.02.11>
24. Du, Y., Cui, X., Sidorenkov, G., Groen, H. J. M., Vliegenthart, R., Heuvelmans, M. A., ... de Bock, G. H. (2020). Lung cancer occurrence attributable to passive smoking among never smokers in China: a systematic review and meta-analysis. *Translational lung cancer research*, 9(2), 204-217.

<https://doi.org/10.21037/tlcr.2020.02.11>

25. Huber, R. M., Hansen, K. H., Paz-Ares Rodriguez, L., West, H. L., Reckamp, K. L., Leighl, N. B., ... Camidge, D. R. (2020). Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. *Journal of Thoracic Oncology*, 15(3), 404-415. <https://doi.org/10.1016/j.jtho.2019.11.004>
26. Witlox, W. J. A., Ramaekers, B. L. T., Joore, M. A., Dingemans, A. -M. C., Praag, J., Belderbos, J., ... De Ruyscher, D. K. M. (2020). Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III study. *Radiotherapy and Oncology*, 144, 65-71. <https://doi.org/10.1016/j.radonc.2019.10.016>
27. Cui, X., Han, D., Heuvelmans, M. A., Du, Y., Zhao, Y., Zhang, L., ... Ye, Z. (2020). Clinical characteristics and work-up of small to intermediate-sized pulmonary nodules in a Chinese dedicated cancer hospital. *Cancer biology & medicine*, 17(1), 199-207. <https://doi.org/10.1016/j.cbm.2019.02.008>
28. de Koning, H. J., van der Aalst, C. M., de Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., ... Oudkerk, M. (2020). Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. *New England Journal of Medicine*, 382(6), 503-513. <https://doi.org/10.1056/NEJMoa1911793>
29. Heist, R. S., Garon, E. B., Tan, D. S. W., Groen, H. J. M., Seto, T., Smit, E. F., ... Wolf, J. (2020). Accurate Detection of METex14 Mutations in Non-Small Cell Lung Cancer (NSCLC) with Comprehensive Genomic Sequencing: Results from the GEOMETRY Mono-1 Study. *Journal of Thoracic Oncology*, 15(2), S30-S31.
30. Holleman, M. S., Al, M. J., Zaim, R., Groen, H. J. M., & Uyl-de Groot, C. A. (2020). Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. *European Journal of Health Economics*, 21(1), 153-164. <https://doi.org/10.1016/j.ehecon.2019.01.003>
31. all participants of NVALT Immunotherapy Register (see addendum), Smit, H. J. M., Aerts, J., van den Heuvel, M., Hiltermann, T. J. N., Bahce, I., ... Groen, H. J. M. (2020). Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry. *Lung Cancer*, 140, 107-112. <https://doi.org/10.1016/j.lungcan.2019.12.011>
32. Nanou, A., Miller, M. C., Zeune, L. L., de Wit, S., Punt, C. J. A., Groen, H. J. M., ... Terstappen, L. W. M. M. (2020). Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival. *British Journal of Cancer*. <https://doi.org/10.1038/s41416-019-0726-9>
33. Xia, C., Rook, M., Pelgrim, G. J., Sidorenkov, G., Wisselink, H. J., van Bolhuis, J. N., ... Vliegenthart, R. (2020). Early imaging biomarkers of lung cancer, COPD and coronary artery disease in the general population: rationale and design of the ImaLife (Imaging in Lifelines) Study. *European Journal of Epidemiology*, 35(1), 75-86. <https://doi.org/10.1007/s10654-019-00519-0>
34. Han, D., Heuvelmans, M. A., van der Aalst, C. M., van Smoorenburg, L. H., Dorrius, M. D., Rook, M., ... Oudkerke, M. (2020). New Fissure-Attached Nodules in Lung Cancer Screening: A Brief Report From The NELSON Study. *Journal of Thoracic Oncology*, 15(1), 125-129. <https://doi.org/10.1016/j.jtho.2019.09.193>
35. Du, Y., Lin, Q., Sidorenkov, G., Vonder, M., Cai, J., de Bock, G. H., ... Liu, S. (2020). Computed Tomography Screening for Early Lung Cancer, COPD and Cardiovascular Disease in Shanghai: Rationale and Design of a Population-based Comparative Study. *Academic Radiology*. <https://doi.org/10.1016/j.acra.2020.01.020>
36. 2019
37. Tamminga, M., de Wit, S., Schuurings, E., Timens, W., Terstappen, L. W. M. M., Hiltermann, T. J. N., & Groen, H. J. M. (2019). Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapy. *Translational lung cancer research*, 8(6), 854-+. <https://doi.org/10.21037/tlcr.2019.11.06>
38. PALGA Grp, Hermans, B. C. M., Derks, J. L., Thunnissen, E., van Suylen, R. J., den Bakker, M. A., ... Dingemans, A. M. C. (2019). DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile. *Lung Cancer*, 138, 102-108. <https://doi.org/10.1016/j.lungcan.2019.10.010>
39. Hermans, B. C. M., Derks, J., Groen, H. J. M., Stigt, J. A., van Suylen, R. J., Hillen, L. M., ... Dingemans, A-M. C. (2019). Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype. *Endocrine Connections*, 8(12), 1600-1606. <https://doi.org/10.1530/EC-19-0372>
40. Sidorenkov, G., Nagel, J., Meijer, C., Duker, J. J., Groen, H. J. M., Halmos, G. B., ... de Bock, G. H. (2019). The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient's perspective. *Journal of translational medicine*, 17(1), [374].

<https://doi.org/10.1016/j.annonc.2019.04.019>

41. Heist, R. S., Seto, T., Han, J.-Y., Reguart, N., Garon, E. B., Groen, H. J. M., ... Wolf, J. (2019). Capmatinib (inc280) in met delta ex14-mutated advanced non-small cell lung cancer (nscl): efficacy data from the phase 2 geometry mono-1 study. *Neuro-Oncology*, 21, 56.
42. Heist, R. S., Wolf, J., Seto, T., Han, J. -Y., Reguart, N., Groen, H. J. M., ... Garon, E. B. (2019). Capmatinib (INC280) in MET Delta EX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study. *Journal of Thoracic Oncology*, 14(11), S1126.
43. Meng, P., Rybczynska, A. A., Wei, J., Terpstra, M. M., Timens, W., Schuurin, E., ... Van den Berg, A. (2019). Detecting therapy-guiding aberrations in platelets and plasma at the transcriptome level in non-small-cell lung cancer. *Annals of Oncology*, 30, [UNSP mdz413.025]. <https://doi.org/10.1016/j.annonc.2019.04.019>
44. Lee, D. H., Kim, D-W., Camidge, D. R., Langer, C. J., Huber, R. M., Tiseo, M., ... Ahn, M-J. (2019). Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial. *Annals of Oncology*, 30, 634-635.
45. Cui, X., Heuvelmans, M. A., Han, D., Zhao, Y., Fan, S., Zheng, S., ... Ye, Z. (2019). Comparison of Veterans Affairs, Mayo, Brock classification models and radiologist diagnosis for classifying the malignancy of pulmonary nodules in Chinese clinical population. *Translational lung cancer research*, 8(5), 605-613. <https://doi.org/10.21037/tlcr.2019.09.17>
46. Burgers, S. A., de Gooijer, C., Cornelissen, R., Aerts, J. G., Biesma, B., Heemst, R. V., ... Stigt, J. (2019). Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19). *Annals of Oncology*, 30.
47. NVALT Study Grp, Groen, H. J. M., van der Heijden, E. H. F. M., Klinkenberg, T. J., Biesma, B., Aerts, J., ... Dingemans, A-M. C. (2019). Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study. *British Journal of Cancer*, 121(5), 372-377. <https://doi.org/10.1038/s41416-019-0533-3>
48. Lindsay, C. R., Blackhall, F. H., Carmel, A., Fernandez-Gutierrez, F., Gazzaniga, P., Groen, H. J. M., ... Michiels, S. (2019). EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer. *European Journal of Cancer*, 117, 60-68. <https://doi.org/10.1016/j.ejca.2019.04.019>
49. Tamminga, M., de Wit, S., Hiltermann, T. J. N., Timens, W., Schuurin, E., Terstappen, L. W. M. M., & Groen, H. J. M. (2019). Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. *Journal for immunotherapy of cancer*, 7(1), [173]. <https://doi.org/10.1016/j.jco.2019.04.019>
50. Willemsen, A. E. C. A. B., Krausz, S., Ligtenberg, M. J. L., Grunberg, K., Groen, H. J. M., Voest, E. E., ... van Herpen, C. M. L. (2019). Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations. *British Journal of Cancer*, 121(1), 34-36. <https://doi.org/10.1038/s41416-019-0489-3>
51. Speel, E-J. M., Hermans, B. C., Derks, J. L., Thunnissen, E., van Suylen, R. J., den Bakker, M. A., ... Dingemans, A-M. C. (2019). A high percentage of LCNEC shows DLL3 expression in association with molecular subtypes and neuroendocrine markers. *Cancer Research*, 79(13). <https://doi.org/10.1158/1538-7445.AM2019-487>
52. Kok, K., Wei, J., Rybczynska, A. A., Meng, P., Terpstra, M. M., van der Wekken, A. J., ... van den Berg, A. (2019). An all-in-one transcriptome-based assay to identify therapy-related biomarkers in lung cancer. *Cancer Research*, 79(13). <https://doi.org/10.1158/1538-7445.SABCS18-2989>

2021

1. Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC

Wei, J., Meng, P., Terpstra, M. M., van Rijk, A., Tamminga, M., Scherpen, F., Ter Elst, A., Alimohamed, M. Z., Johansson, L. F., Stigt, J., Gijtenbeek, R. P. G., van Putten, J., Hiltermann, T. J. N., Groen, H. J. M., Kok, K., van der Wekken, A. J. & van den Berg, A., 19-Feb-2021, In: *Targeted oncology*. 12 p.

2. Computed Tomography Screening for Early Lung Cancer, COPD and Cardiovascular Disease in Shanghai: Rationale and Design of a Population-based Comparative Study

Du, Y., Lin, Q., Sidorenkov, G., Vonder, M., Cai, J., de Bock, G. H., Guan, Y., Xia, Y., Zhou, X., Zhang, D., Rook, M., Vliegthart, R., Heuvelmans, M., Dorrius, M., Ooijen, van, P., Groen, H. J. M., Harst, van der, P., Xiao, Y., Ye, Z., Xie, X. & 4 others, , Jan-2021, In: *Academic Radiology*. 28, 1, p. 36-45 10 p.

3. Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients

- Meng, P., de Bruyn-Rybczynska, A., Wei, J., Terpstra, M. M., Timens, W., Schuurung, E., Hiltermann, J., Groen, H. J. M., van der Wekken, A. J., van den Berg, A. & Kok, K., 28-Jan-2021, (E-pub ahead of print) In: medRxiv.
4. F-18-FDG PET/CT Scans Can Identify Sub-Groups of NSCLC Patients with High Glucose Uptake in the Majority of Their Tumor Lesions
Hendriks, A. M., Brouwers, A. H., Giannopoulos, P., Lefrandt, J. D., Timens, W., Groen, H. J. M., de Bock, G. H. & Jalving, M., 2021, In: Journal of Cancer. 12, 2, p. 562-570 9 p.
5. Individual patient data meta-analysis of prophylactic cranial irradiation in locally advanced non-small cell lung cancer
Witlox, W. J. A., Ramaekers, B. L. T., Lacas, B., Le Pechoux, C., Pignon, J-P., Sun, A., Wang, S-Y., Hu, C., Redman, M., van der Noort, V., Li, N., Guckenberger, M., van Tinteren, H., Groen, H. J. M., Joore, M. A. & De Ruyscher, D. K. M., May-2021, In: Radiotherapy and Oncology. 158, p. 40-47 8 p.
6. Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands
Santeon NSCLC Study Group, Cramer-van der Welle, C. M., Verschueren, M. V., Tonn, M., Peters, B. J. M., Schramel, F. M. N. H., Klungel, O. H., Groen, H. J. M. & van de Garde, E. M. W., 18-Mar-2021, (E-pub ahead of print) In: Scientific Reports. 11, 9 p., 6306.
7. Seasonal prevalence and characteristics of low-dose CT detected lung nodules in a general Dutch population
Lancaster, H. L., Heuvelmans, M. A., Pelgrim, G. J., Rook, M., Kok, M. G. J., Aown, A., de Bock, G. H., van den Berge, M., Groen, H. J. M. & Vliegenthart, R., 28-Apr-2021, (E-pub ahead of print) In: Scientific Reports. 11, 1, 10 p., 9139.
8. Simultaneous Identification of EGFR, KRAS, ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics
Zhang, T., Xu, Z., Liu, G., Jiang, B., de Bock, G. H., Groen, H. J. M., Vliegenthart, R. & Xie, X., 10-Apr-2021, In: Cancers. 13, 8, 14 p.
9. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial
NVALT19 study group, de Gooijer, C. J., van der Noort, V., Stigt, J. A., Baas, P., Biesma, B., Cornelissen, R., van Walree, N., van Heemst, R. C., Soud, M. Y-E., Groen, H. J. M., den Brekel, A. J. S., Buikhuisen, W. A., Bootsma, G. P., Dammeijer, F., van Tinteren, H., Lalezari, F., Aerts, J. G. & Burgers, J. A., 27-Jan-2021, (E-pub ahead of print) In: The Lancet. Respiratory Medicine. 8 p. 2020
10. A Subsolid Nodules Imaging Reporting System (SSN-IRS) for Classifying 3 Subtypes of Pulmonary Adenocarcinoma
Cui, X., Heuvelmans, M. A., Fan, S., Han, D., Zheng, S., Du, Y., Zhao, Y., Sidorenkov, G., Groen, H. J. M., Dorrius, M. D., Oudkerk, M., de Bock, G. H., Vliegenthart, R. & Ye, Z., Jul-2020, In: Clinical lung cancer. 21, 4, p. 314-+ 16 p.
11. An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients
Wei, J., Rybczynska, A. A., Meng, P., Terpstra, M., Saber, A., Sietzema, J., Timens, W., Schuurung, E., Hiltermann, T. J. N., Groen, H. J. M., van der Wekken, A. J., van den Berg, A. & Kok, K., Oct-2020, In: Cancers. 12, 10, p. 1-17 18 p., 2843.
12. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
Huber, R. M., Hansen, K. H., Paz-Ares Rodriguez, L., West, H. L., Reckamp, K. L., Leighl, N. B., Tiseo, M., Smit, E. F., Kim, D-W., Gettinger, S. N., Hochmair, M. J., Kim, S-W., Langer, C. J., Ahn, M-J., Kim, E. S., Kerstein, D., Groen, H. J. M. & Camidge, D. R., Mar-2020, In: Journal of Thoracic Oncology. 15, 3, p. 404-415 12 p.
13. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
GEOMETRY Mono-1, Wolf, J., Seto, T., Han, J-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Hida, T., de Jonge, M., Orlov, S. V., Smit, E. F., Souquet, P-J., Vansteenkiste, J., Hochmair, M., Felip, E., Nishio, M., Thomas, M., Ohashi, K., Toyozawa, R. & 13 others, , 3-Sep-2020, In: New England Journal of Medicine. 383, 10, p. 944-957 14 p.
14. Clinical characteristics and work-up of small to intermediate-sized pulmonary nodules in a Chinese dedicated cancer hospital

- Cui, X., Han, D., Heuvelmans, M. A., Du, Y., Zhao, Y., Zhang, L., Groen, H. J. M., de Bock, G. H., Dorrius, M. D., Oudkerk, M., Vliegthart, R. & Ye, Z., 15-Feb-2020, In: *Cancer biology & medicine*. 17, 1, p. 199-207 9 p.
15. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation
Meng, P., Koopman, B., Kok, K., Elst, ter, A., Schuurung, E., van Kempen, L., Timens, W., Hiltermann, J., Groen, H. J. M., van den Berg, A. & van der Wekken, A. J., Aug-2020, In: *Lung Cancer*. 146, p. 358-361 4 p.
16. Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients
Leest, P. V. D., Boonstra, P. A., Elst, A. T., Kempen, L. C. V., Tibbesma, M., Koopmans, J., Miedema, A., Tamminga, M., Groen, H. J. M., Reyners, A. K. L. & Schuurung, E., May-2020, In: *Cancers*. 12, 5, 14 p., 1222.
17. Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer
Perakis, S. O., Weber, S., Zhou, Q., Graf, R., Hojas, S., Riedl, J. M., Gerger, A., Dandachi, N., Balic, M., Hoefler, G., Schuurung, E., Groen, H. J. M., Geigl, J. B., Heitzer, E. & Speicher, M. R., 23-Sep-2020, In: *ESMO Open*. 5, 5, 11 p., 000872.
18. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
Holleman, M. S., Al, M. J., Zaim, R., Groen, H. J. M. & Uyl-de Groot, C. A., Feb-2020, In: *European Journal of Health Economics*. 21, 1, p. 153-164 12 p.
19. Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study
Du, Y., Sidorenkov, G., Heuvelmans, M. A., Groen, H. J. M., Vermeulen, K. M., Greuter, M. J. W. & de Bock, G. H., 18-Aug-2020, In: *European Journal of Cancer*. 135, p. 121-129 9 p.
20. Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch(R) and ISET
Tamminga, M., Andree, K. C., Hiltermann, T. J. N., Jayat, M., Schuurung, E., van den Bos, H., Spierings, D. C. J., Lansdorp, P. M., Timens, W., Terstappen, L. W. M. M. & Groen, H. J. M., 7-Apr-2020, In: *Cancers*. 12, 4, 15 p., 896.
21. Early imaging biomarkers of lung cancer, COPD and coronary artery disease in the general population: rationale and design of the ImaLife (Imaging in Lifelines) Study
Xia, C., Rook, M., Pelgrim, G. J., Sidorenkov, G., Wisselink, H. J., van Bolhuis, J. N., van Ooijen, P. M. A., Guo, J., Oudkerk, M., Groen, H., van den Berge, M., van der Harst, P., Dijkstra, H., Vonder, M., Heuvelmans, M. A., Dorrius, M. D., De Deyn, P. P., de Bock, G. H., Dotinga, A. & Vliegthart, R., Jan-2020, In: *European Journal of Epidemiology*. 35, 1, p. 75-86 12 p.
22. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry
all participants of NVALT Immunotherapy Register (see addendum), Smit, H. J. M., Aerts, J., van den Heuvel, M., Hiltermann, T. J. N., Bahce, I., Smit, E. F., Dingemans, A-M. C., Hendriks, L. E., Stigt, J. A., Schramel, F. M. N. H., van Tinteren, H. & Groen, H. J. M., Feb-2020, In: *Lung Cancer*. 140, p. 107-112 6 p.
23. Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial
Brouns, A. J. W. M., Hendriks, L. E. L., van der Noort, V., van de Borne, B. E. E. M., Schramel, F. M. N. H., Groen, H. J. M., Biesma, B., Smit, H. J. M. & Dingemans, A-M. C., 24-Jun-2020, In: *Frontiers in Oncology*. 10, 5 p., 890.
24. Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III study
Witlox, W. J. A., Ramaekers, B. L. T., Joore, M. A., Dingemans, A. -M. C., Praag, J., Belderbos, J., Tissing-Tan, C., Herder, G., Haitjema, T., Ubbels, J. F., Lagerwaard, J., El Sharouni, S. Y., Stigt, J. A., Smit, E. F., van Tinteren, H., van der Noort, V., Groen, H. J. M. & De Ruyscher, D. K. M., Mar-2020, In: *Radiotherapy and Oncology*. 144, p. 65-71 7 p.
25. Immune microenvironment composition in non-small cell lung cancer and its association with survival
Tamminga, M., Hiltermann, T. J. N., Schuurung, E., Timens, W., Fehrmann, R. S. N. & Groen, H. J.

M., 12-Jun-2020, In: Clinical & translational immunology. 9, 6, 13 p., 1142.

2022

1.

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis.

Planchard D, Besse B, Groen HJM, Hashemi SMS, Mazieres J, Kim TM, Quoix E, Souquet PJ, Barlesi F, Baik C, Villaruz LC, Kelly RJ, Zhang S, Tan M, Gasal E, Santarpia L, Johnson BE.

J Thorac Oncol. 2022 Jan;17(1):103-115. doi: 10.1016/j.jtho.2021.08.011. Epub 2021 Aug 26.

PMID: 34455067 Clinical Trial.

2.

89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer.

Kok IC, Hooiveld JS, van de Donk PP, Giesen D, van der Veen EL, Lub-de Hooge MN, Brouwers AH, Hiltermann TJN, van der Wekken AJ, Hijmering-Kappelle LBM, Timens W, Elias SG, Hospers GAP, Groen HJM, Uyterlinde W, van der Hiel B, Haanen JB, de Groot DJA, Jalving M, de Vries EGE.

Ann Oncol. 2022 Jan;33(1):80-88. doi: 10.1016/j.annonc.2021.10.213. Epub 2021 Nov 1.

PMID: 34736925

3.

Antiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.

Remon J, Lacas B, Herbst R, Reck M, Garon EB, Scagliotti GV, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen HJM, Heymach JV, Mandrekar SJ, Okamoto I, Neal JW, Heist RS, Planchard D, Pignon JP, Besse B; ANSELMA collaborative group.

Eur J Cancer. 2022 May;166:112-125. doi: 10.1016/j.ejca.2022.02.002. Epub 2022 Mar 11.

PMID: 35286903 Review.

4.

Airflow Limitation Increases Lung Cancer Risk in Smokers: The Lifelines Cohort Study.

Du Y, Sidorenkov G, Groen HJM, Heuvelmans MA, Vliegenthart R, Dorrius MD, Timens W, de Bock GH.

Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1442-1449. doi:

10.1158/1055-9965.EPI-21-1365.

PMID: 35534234

5.

Cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer.

Witlox WJA, Ramaekers BLT, Lacas B, Le Pechoux C, Sun A, Wang SY, Hu C, Redman M, van der Noort V, Li N, Guckenberger M, van Tinteren H, Hendriks LEL, Groen HJM, Joore MA, De Ruyscher DKM.

Radiother Oncol. 2022 May;170:95-101. doi: 10.1016/j.radonc.2022.02.036. Epub 2022 Mar 5.

PMID: 35259416 Clinical Trial.

6.

Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.

Steeghs EMP, Groen HJM, Schuurin E, Aarts MJ, Damhuis RAM, Voorham QJM; PATH consortium, Ligtenberg MJL, Grunberg K.

Lung Cancer. 2022 May;167:87-97. doi: 10.1016/j.lungcan.2022.04.001. Epub 2022 Apr 4.

PMID: 35461050

7.

Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature.

Koopman B, Groen HJM, Schuurin E, Hiltermann TJN, Timens W, den Dunnen WFA, van den Berg A, Ter Elst A, van Kruchten M, Kluiver JL, Hiddinga BI, Hijmering-Kappelle LBM, Groves MR, Vilacha JF, van Kempen LC, van der Wekken AJ.

Clin Lung Cancer. 2022 Mar;23(2):e104-e115. doi: 10.1016/j.clcc.2021.06.011. Epub 2021 Jul 3.

PMID: 34325996 Review.

8.

Decoding circulating tumor DNA to identify durable benefit from immunotherapy in lung cancer.

Donker HC, Schuurig E, Heitzer E, Groen HJM.

Lung Cancer. 2022 Aug;170:52-57. doi: 10.1016/j.lungcan.2022.05.013. Epub 2022 May 25.

PMID: 35716631

9.

CT characteristics of solid pulmonary nodules of never smokers versus smokers: A population-based study.

Cai J, Vonder M, Heuvelmans MA, Pelgrim GJ, Rook M, Kramer G, Sidorenkov G, Groen HJM, de Bock GH, Vliegenthart R.

Eur J Radiol. 2022 Sep;154:110410. doi: 10.1016/j.ejrad.2022.110410. Epub 2022 Jun 14.

PMID: 35777080

10.

Association between Chest CT-defined Emphysema and Lung Cancer: A Systematic Review and Meta-Analysis.

Yang X, Wisselink HJ, Vliegenthart R, Heuvelmans MA, Groen HJM, Vonder M, Dorrius MD, de Bock GH.

Radiology. 2022 Aug;304(2):322-330. doi: 10.1148/radiol.212904. Epub 2022 May 3.

PMID: 35503012

11.

Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non-Small-Cell Lung Cancer in the Netherlands.

Wolff HB, Steeghs EMP, Mfumbilwa ZA, Groen HJM, Adang EM, Willems SM, Grunberg K, Schuurig E, Ligtenberg MJL, Tops BBJ, Coupe VMH.

JCO Precis Oncol. 2022 Jul;6:e2200201. doi: 10.1200/PO.22.00201.

PMID: 35834758 Free PMC article.

12.

Leukapheresis increases circulating tumour cell yield in non-small cell lung cancer, counts related to tumour response and survival.

Tamminga M, Andree KC, van den Bos H, Hiltermann TJN, Mentink A, Spierings DCJ, Lansdorp P, Timens W, Schuurig E, Terstappen LWMM, Groen HJM.

Br J Cancer. 2022 Feb;126(3):409-418. doi: 10.1038/s41416-021-01634-0. Epub 2021 Nov 30.

PMID: 34848855 Free PMC article.

13.

Lung cancer screening with low-dose CT: Simulating the effect of starting screening at a younger age in women.

Du Y, Sidorenkov G, Heuvelmans MA, Vliegenthart R, Groen HJM, Greuter MJW, de Bock GH.

Eur J Radiol. 2022 Mar;148:110182. doi: 10.1016/j.ejrad.2022.110182. Epub 2022 Jan 29.

PMID: 35121333

14.

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer.

Gijtenbeek RGP, van der Noort V, Aerts JGJV, Staal-van den Brekel JA, Smit EF, Krouwels FH, Wilschut FA, Hiltermann TJN, Timens W, Schuurig E, Janssen JDJ, Goosens M, van den Berg PM, de Langen AJ, Stigt JA, van den Borne BEEM, Groen HJM, van Geffen WH, van der Wekken AJ.

ERJ Open Res. 2022 Oct 17;8(4):00239-2022. doi: 10.1183/23120541.00239-2022. eCollection 2022 Oct.

PMID: 36267895 Free PMC article.

15.

Association between visual emphysema and lung nodules on low-dose CT scan in a Chinese Lung Cancer Screening Program (Nelcin-B3).

Yang X, Dorrius MD, Jiang W, Nie Z, Vliegenthart R, Groen HJM, Heuvelmans MA, Sidorenkov G, Vonder M, Ye Z, de Bock GH.

Eur Radiol. 2022 Dec;32(12):8162-8170. doi: 10.1007/s00330-022-08884-3. Epub 2022 Jun 9.

PMID: 35678862 Free PMC article.

16.

The Presence of EGFR T790M in TKI-Naive Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare.

Li W, Kok K, Tan GW, Meng P, Mastik M, Rifaela N, Scherpen F, Hiltermann TJN, Groen HJM, Wekken AJV, van den Berg A.

Cancers (Basel). 2022 Jul 19;14(14):3511. doi: 10.3390/cancers14143511.

PMID: 35884570 Free PMC article.

17.

Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC.

Johnson BE, Baik CS, Mazieres J, Groen HJM, Melosky B, Wolf J, Zadeh Vosta Kolaei FA, Wu WH, Knoll S, Ktiouet Dawson M, Johns A, Planchard D.

JTO Clin Res Rep. 2022 Apr 6;3(5):100324. doi: 10.1016/j.jtocrr.2022.100324. eCollection 2022 May.

PMID: 35592617 Free PMC article.

18.

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort.

Koopman B, Kuijpers CCHJ, Groen HJM, Timens W, Schuurin E, Willems SM, van Kempen LC.

Diagnostics (Basel). 2022 Mar 9;12(3):668. doi: 10.3390/diagnostics12030668.

PMID: 35328221 Free PMC article.

19.

A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands.

Ten Berge DMHJ, Aarts MJ, Groen HJM, Aerts JGJV, Kloover JS.

Eur J Cancer. 2022 Apr;165:195-204. doi: 10.1016/j.ejca.2022.01.038. Epub 2022 Mar 3.

PMID: 35248841

20.

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.

Gettinger SN, Huber RM, Kim DW, Bazhenova L, Hansen KH, Tiseo M, Langer CJ, Paz-Ares Rodriguez LG, West HL, Reckamp KL, Weiss GJ, Smit EF, Hochmair MJ, Kim SW, Ahn MJ, Kim ES, Groen HJM, Pye J, Liu Y, Zhang P, Vranceanu F, Camidge DR.

JTO Clin Res Rep. 2022 Jul 31;3(9):100385. doi: 10.1016/j.jtocrr.2022.100385. eCollection 2022 Sep.

PMID: 36065449 Free PMC article.

21.

Investigation of the added value of CT-based radiomics in predicting the development of brain metastases in patients with radically treated stage III NSCLC.

Keek SA, Kayan E, Chatterjee A, Belderbos JSA, Bootsma G, van den Borne B, Dingemans AC, Gietema HA, Groen HJM, Herder J, Pitz C, Praag J, De Ruyscher D, Schoenmaekers J, Smit HJM, Stigt J, Westenend M, Zeng H, Woodruff HC, Lambin P, Hendriks L.

Ther Adv Med Oncol. 2022 Aug 22;14:17588359221116605. doi: 10.1177/17588359221116605. eCollection 2022.

PMID: 36032350 Free PMC article.

[Projects](#)

[Memberships](#) AACR, ASCO, Cancer Discovery, NVALT, ESMO, Koninklijk Natuurkundig Genootschap

[Other Relevant Information](#)